Curriculum Vitae

JODY JONATHAN HAIGH, PH.D.
jody.haigh@umanitoba.ca

Contact Information



- MOB: 204-558-8450
- Work: 204-787-2134
- Address: 760 Jessie Ave, Winnipeg MB, Canada R3M 1A6
- Canadian Citizen

Current Position

April 1, 2021-present

- **Full Professor**
  Tenured
  Department of Pharmacology and Therapeutics
  Rady Faculty of Health Sciences
  University of Manitoba

July 1, 2020-present

- **Head of Cancer Modeling and Imaging Core (CMIC)**
  CancerCare Manitoba Research Institute
  CancerCare Manitoba

August 1, 2018-present

- **Senior Scientist**
  CancerCare Manitoba Research Institute
  CancerCare Manitoba

Previous Positions

December 1, 2021-March 31, 2023

- **Co-Director of Research** CancerCare Manitoba Research Institute
  CancerCare Manitoba

August 1, 2018-March 31, 2021

- **Associate Professor**
  Tenure-track probationary position
  Department of Pharmacology and Therapeutics
  Rady Faculty of Health Sciences
  University of Manitoba

August 1, 2013-July 1, 2018

- **Associate Professor**
  Research only position
  Primary appointment-Australian Centre for Blood Diseases (*ACBD*)
  Monash University
  Melbourne, Australia

September 15, 2015-July 1, 2018

- **Associate Professor**
  Research only position
  Secondary appointment-Australian Regenerative Medicine Institute (*ARMI*)
  Monash University
  Melbourne, Australia

November 1, 2009-July 1, 2013

- **Assistant Professor**
  Nominal 10% position
  Department for Molecular Biomedical Research (DMBR)
  Ghent University
  Ghent, Belgium

August 1, 2004-July 1, 2013

- **Group Leader**
  Research only position
  VIB
  Ghent, Belgium

Education and Training

February 15, 2000-March 31, 2004

- **Postdoctoral fellow**
  Samuel Lunenfeld Research Institute
  Professor Andras Nagy lab
  Toronto, Canada
  Project 1: "The Role of VEGF-A Signaling in Organogenesis and Disease Progression." (Project Leader-NCIC Grant)
  Project 2: “ES cell-based screens for identifying novel angiogenic molecules.” (Project Co-Leader: Industrial Funding form Bayer Pharmaceuticals, USA)

November 15, 1995-February 1, 2000

- **Ph.D. Biochemistry**
  Vienna Biocentre International Ph.D. program
  IMP/University of Vienna
  Professor Erwin F. Wagner lab
  Vienna, Austria
  Thesis: "The Role of VEGF in Bone Development and Vascular Malformations."

September 11, 1992-October 28, 1995

- **M.Sc. Biochemistry**
  Queen’s Cancer Research Institute,
  Queen’s University
  Professor Peter Greer lab
  Kingston, Canada

September 11, 1988-May 29, 1992

- **B.Sc.H. Life Sciences**
  Queen’s University
  Kingston, Canada

Awards and Fellowships

August 1, 2013-August 1, 2015

- **Larkins Fellowship-Monash University**
  Value=$630,000 ($480K-salary support and consumables, $150K-Equipment purchase)

January 1, 2011-January 1, 2016

- **Tier II Canada Research Chair in Regenerative Medicine***
  (Queen's University, Canada)
  Value=$700,000 ($100K/year salary support + 200K CFI component)
  *Position Declined by Applicant due to personal reasons

June 1, 2001-March 31, 2004

- **Terry Fox National Cancer Institute of Canada (NCIC) Postdoctoral Fellowship** ($40,000/annum)

November 15, 1995-December 15, 1999

- **Vienna Biocentre International PhD Studentship**
  ($20,000/annum)

September 1, 1994-October 28, 1995

- **Queen's Graduate Award** ($5,000)

Research Accomplishments

University of Manitoba

(August 2018-present) Started out **75% Research, 25% Teaching and Service** and this has changed to **60% Research**, **40% Teaching and Service Position**

Research Funding Support

Canada

August 1, 2018-present

- **CCMF Project Grant**
  "Novel therapeutic strategies targeting relapse-inducing cells in T-cell acute"
  Role: Co-Applicant with Dr. Credic Tremblay (PI)
  Duration: July 2023-July 2024
  Amount: $75,000

- **CCMF Project Grant**
  "Characterizing and Targeting the Defects Giving Rise to Colorectal Cancer"
  Role: Co-Applicant with Dr. Kirk McManus (PI)
  Duration: July 2023-July 2025
  Amount: $150,000

- **CCMF Multidisciplinary Team Grant**
  Title: Development of in vitro and in vivo platforms for humanized leukemia research and pre-clinical CAR-T therapy validation.
  Role: Principal Investigator
  Duration: July 2023-July-2026
  Amount: $450,000

- **CCMR-Cancer Modeling and Imaging Core Platform Grant**
  Title: "Cancer modelling and Imaging Platform"
  Role: Principal Investigator
  Duration: July 2023-July 2024
  Amount: $275,624

- **ALS Canada/Brain Canada**
  Title: *DNA damage driven motor disturbance in ALS: An ERVK integrase transgenic mouse model*

Role: Co-Investigator
Duration: Jan. 2023-Jan 2025
Amount: $124,900

- **RDMM/MWS Grant**
  Title: "*Development of novel mouse models to study Mowat-Wilson Syndrome*"
  Role: Principal Investigator
  Duration October 2022-October 2023
  Amount: $25,000

- **CCMF Project Grant**
  Title: "*Deciphering the Oncogenic Role of ZEB2 in B Cell Precursor Leukemia"*
  Role: Principal Investigator
  Duration July 2022-July 2024
  Amount: $150,000

- **CCMR-CCMF Platform Grant**
  Title: "Cancer modelling and Imaging Platform"
  Role: Principal Investigator
  Duration: July 2022-July 2023
  Amount: $152,000

- **John Evans Leadership Fund (JELF)-CFI**
  Generation of In vivo Imaging Platform for Cancer Models
  Duration:2021-2026
  Amount: $442,442

- **RIOH Core Facility Grant-CCMF**
  Title: *"*Patient-Derived Xenograft Core Facility*"*
  Role: Principal Investigator
  Duration: July 2020-July 2021
  Amount: $86,000/year X 2 years

- **Research Manitoba Rapid Response Grants for COVID-19**
  Title: *"DEVELOPMENT OF HUMANIZED ACE2 MOUSE MODELS FOR COVID-19 RESEARCH"*
  Role: Principal Investigaor
  Duration: June, 2020- June, 2021
  Amount: $65,500

- **MITACS Accelerate International Grant**
  Title: "*Improving Q-RT-PCR screening for COVID-19 by tracking viral variants."*

Role: Principal Investigator
Co-Applicant: BioXplor, Inc
Duration: July-October 2020
Amount: $15,000

- **CIHR Project Operating Grant**
  Title: *"EMT Transcription factor corruption of epigenetic regulators in AML"*
  Role: Principal Investigator
  Duration: 2019-2024
  Amount: $990,676.00

- **CCMF Pilot Grant**
  Title: *"Creation of Novel Inducible Cas9 models for in vivo Cancer Studies"*
  Role: Principal Investigator
  Duration: 2019-2020
  Amount: $50,000.00

- **CCMF Infrastructure Grant**
  For purchase of IVC racks
  Amount: $37,000

- **University of Manitoba/CancerCare Manitoba lab start-up funds**
  Duration: 2018-2021
  Amount: $425,000

Australia **100% Research Position**

August 1, 2013-July 1, 2018

- **NHMRC Project Grant (#1141081)**
  Title: "Role of ZEB2/SNAI1 in epigenetic remodeling and myeloid cell transformation"
  Role: Principal Investigator
  Duration: 2018-2020*
  Amount: $809,515.50
  (*Relinquished PI role upon moving to Canada)

- **NHMRC Project Grant (#1104441)**
  Title: *"Role of ZEB/NuRD interactions in Hematopoieisis and Lymphoid Malignancies"*
  Role: Principal Investigator
  Duration: 2016-2018
  Amount: $810,494.00

- **NHMRC Project Grant (#1086662)**
  Title: *"Eradicating leukemic stem cells by targeting the arginine methyltransferase PRMT5"*
  Role: Co-investigator
  Duration: 2015-2018
  Amount: $50,000 for Haigh lab

- **NHMRC Project Grant (#1047995)**
  Title: *"Novel Genes Involved in Leukemia development"*
  Role: Principal Investigator
  Duration: 2013-2016
  Amount: $628,237.35

- **NHMRC Project Grant (#1104441)**
  Title: *"Finding Novel RNAs in Heart and Blood Vessel Development"*
  Role: Principal Investigator
  Duration: 2013-2016
  Amount: $606,767.85

Belgium

November 1, 2009-July 1, 2013 **90% Research Position**

- **Interuniversity Attraction Poles (IUAP) Grant (#P707)**
  Role: Co-Investigator
  Duration: 2012-2016
  Amount: $207,000 for Haigh lab

- **Belgium Federation Against Cancer (#F49)**
  Operating Grant
  Role: Principal Investigator
  Duration: 2012-2014
  Amount: $215,000

- **Flemish Basic Science Foundation (FWO) (#G.0568.13N)**
  Operating Grant
  Role: Principal Investigator
  Duration: 2012-2015
  Amount: $128,000

- **Belgium Federation Against Cancer**
  Operating Grant
  Role: Principal Investigator
  Duration: 2009-2012
  Amount: $283,000

August 1, 2004-November 1, 2009* **100% Research Position**

- **Flemish Basic Science Foundation (FWO)**
  Operating grant
  Role: Co-investigator
  Duration: 2008-2011
  Amount: $180,000 for Haigh lab

- **Interuniversity Attraction Poles (IUAP) Grant**
  Operating Grant
  Role: Co-Investigator
  Duration: 2007-2010
  Amount: $257,000 for Haigh lab

- **Flemish Basic Science Foundation (FWO)**
  Operating Grant
  Role: Co-Investigator
  Duration: 2007-2010

Amount: $129,000 for Haigh lab

- **Flemish Industrial Research Grant (IWT)**
  Operating Grant
  Role: Co-Investigator
  Duration: 2006-2008
  Amount: $386,000 for Haigh lab

- **Association for International Cancer Research (AICR)**
  Operating Grant
  Role: Co-Investigator with Professor Geert Berx
  Duration: 2006-2008
  Amount: $50,0000

***** During this period, I did not have a partial university appointment at Ghent University and could not apply independently for research funding at FWO or act as main supervisor for graduate students and postdocs that limited the growth potential of my lab during this period.

Total research funding obtained since independence in 2004> $8 Million.

Publications

(in reverse chronological order, underlined names are past/present Haigh Lab members, #equal contributions, Papers in RED are first/last author publications, Impact Factors (IF) based upon 2020-2021 data)

AVG IF of all publications=13.63 (N=105)
AVG IF of First/Last Author publications=11.72 (N=28)
Career Citations >9145
H-index=48

Non peer review submitted pre-publication articles.

Large-scale population analysis of SARS-CoV2 whole genome sequences reveals host-mediated viral evolution with emergence of mutations in the viral Spike protein associated with elevated mortality rates.
Carlos Farkas, Andy Mella, **Jody J. Haigh**
medRxiv, posted Oct 27, 2020

Insights on early mutational events in SARS-CoV-2 virus reveal founder effects across geographical regions. Carlos Farkas, Francisco Fuentes-Villalobos, José Luis Garrido, **Jody J Haigh**, María Inés Barría
bioRxiv, posted April 12, 2020

TINC - a method to dissect transcriptional complexes at single locus resolution - reveals novel Nanog regulators in mouse embryonic stem cells. AS Knaupp, M Mohenska, MR Larcombe, E Ford, SM Lim, K Wong, J Chen, J Firas, C Huang, X Liu, T Nguyen, YBY Sun, ML Holmes, P Tripathi, FJ Rossello, J Schröder, CM Nefzger, PP Das, **JJ Haigh**, R Lister, RB Schittenhelm, JM Polo
bioRxiv, posted April 4, 2020

Modeling Braf*-induced thyroid cancer development and drug screening using pluripotent stem cell-derived organoids.* Hélène Lasolle, Andrea Schiavo, Adrien Tourneur, Pierre Gilotay, Bárbara de Faria daFonseca, Lucieli Ceolin, Olivier Monestier, Benilda Aganahi, Laura Chomette, MarinaKisys P olisel, Lieven Haenabalcke, Tim Pieters, Steven Goossens, **Jody Haigh**, Vincent Detours, Ana Luiza, Silva Maia, Sabine Costagliola, Mirian Romaitti
bioRxiv, posted April 02, 2023

Submitted or In Revision

107. *Modeling* Braf*-induced thyroid cancer development and drug screening using pluripotent stem cell-derived organoids.* Hélène Lasolle, Andrea Schiavo, Adrien Tourneur, Pierre Gilotay, Lucieli Ceolin, Olivier Monestier, Benilda Aganahi, Laura Chomette, MarinaKi sys Polisel, Lieven Haenabalcke, Tim Pieters, Steven Goossens, **Jody Haigh**, Vincent Deto urs, Ana Luiza, Silva Maia, Sabine Costagliola, Mirian Romaitti
***Cancer Research*,** Submitted April 17, 2023 [**IF=13.3]**

106. *Asparagine synthetase marks a distinct dependency threshold for cardiomyocyte dedifferentiation.* Yike Zhu, Matthew Ackers-Johnson, Muthu K Shanmugam, Leroy Sivappiragasam Pakkiri, Chester Lee Drum, Chen Yanpu, Johnny Kim, Wilson Lek, Wen Tan, Jiang Jianming, Luu Danh, Anh Tuan, Shi Ling Ng, Peter Yi, Qing Li, **Jody J. Haigh**, Zenia Tiang, A. Mark Richards, Roger Foo
Circulation, In revision [**IF=39.92]**

Published or Accepted

2023

105. *Unveiling the Complexity of Transcription Factor Networks in Hematopoietic Stem Cells: implications for cell therapy and hematological malignancies.* Aissa Benyoucef, Jody J. Haigh, Majorie Brand. *Front. Oncol. 13:1151343. Review Accepted June 14, 2023 (Review)*
[IF=6.244]

104. *Monitoring AKT activity and targeting in live tissue and disease settings using a real-time AKT-FRET biosensor mouse.* James R.W. Conway, Sean C. Warren, Young-Kyung Lee, Andrew T. McCulloch, Astrid Magenau, Victoria Lee, Xanthe L. Metcalf, Janett Stoehr, Katharina Haigh, Lea Abdulkhalek, Cristian S. Guaman, Daniel A. Reed, Kendelle J. Murphy, Brooke A. Pereira, Pauline Mélénec, Sharissa L. Latham, Helen Lenthall, Elissa K. Deenick, Yuanqing Ma, Tri Phan, Elgene Lim, Anthony M. Joshua, Stacey Walters, Shane T. Grey, Yan-Chan Shi, Lei Zhang, Herbert Herzog, David R. Croucher, Andy Philp, David Herrmann, Owen J. Sansom, Jennifer P. Morton, Antonella Papa, **Jody J. Haigh**[#], Max Nobis[*,#], Paul Timpson[*,#]. [*]equal contributions, [#]co-correspondng author
Science Advances, Accepted March 20, 2023, In Press [**IF=14.14]**

103. *STAT5 activation promotes stemness and therapeutic resistance of leukemia-regenerating cells.* Cedric S. Tremblay, Jesslyn Saw, Jacqueline A. Boyle, Katharina Haigh, Veronique Litalien, Hannah McCalmont, Kathryn Evans, Jessica M. Salmon, Richard B. Lock, Stephen M. Jane, **Jody J. Haigh,** and David J. Curtis
Blood Journal, March 29, 2023 [**IF=25.48**]

102. *Dysregulation of Grainyhead-like 3 expression causes widespread developmental defects.* Zihao Deng, Tariq Butt, Benedicta D. Arhatari, Charbel Darido, Alana Auden, Dijina Swaroop, Darren D. Partridge, Katharina Haigh, Thao Nguyen, **Jody J. Haigh**, Marina R. Carpinelli[#] and Stephen M. Jane[#]
[#]co-correspondng author
Dev Dyn, 2023, Jan https://doi.org/10.1002/dvdy.565 [IF=3.78]

2022

101. *GATA3 mediates nonclassical β-catenin signaling in skeletal cell fate determination.*
Maruyama T., Hasegawa, D., Valenta, T., **Haigh, J.J.**, Bouchard, M., Basler, K., Hsu, W.
Science Advances 2022, Nov 8:1-11 [**IF=14.14**]

100. *JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.* Aissa Benyoucef, Katharina Haigh, Andrew Cuddihy, **Jody J. Haigh**
Leukemia *2022,* Oct 13. 36:2802-2816 [**IF=11.53**]

99. *Annotate my genomes: an easy-to-use pipeline to improve genome annotation and uncover neglected genes by hybrid RNA sequencing.* Carlos Farkas, Antonia Recabal, Daniel Candia-Herrera, Maria de los Angeles Garcia, **Jody J. Haigh**, Estefania Tarifeño-Saldivia* and Teresa Caprile*
Gigascience, 2022, Dec 11:1-14 [IF=7.66]

98. *The MEF2C oncogene opposes NOTCH1 in T versus B lineage decision and drives leukemia in the thymus context.* Kirsten Canté-Barrett, Valentina Cordo, Rico Hagelaar, Mariska Meijer, Marloes Nulle, Willem K. Smits, Joris Jansen, **Jody J. Haigh**, Steven Goossens, and Jules P.P. Meijerink
JCI insight-2022 Jul 8;7(13): e150363. [**IF=9.48**] {Citations=2}

2021

97. *Interplay between the EMT transcription factor Zeb1 and Zeb2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity.* Jueqiong Wang, Carlos Farkas, Aissa Benyoucef, Catherine Carmichael, Katharina Haigh, Nick Wong, Danny Huylebroeck, Marc P. Stemmler, Simone Brabletz, Thomas Brabletz, Christian Nefzger, Steven Goossens, Geert Berx, Jose M. Polo, **Jody J. Haigh**
PLOS Biology- 2021 19(9): e3001394 [**IF=9.59**] {Citations=10}

96. *Tumor suppressing subtransferable candidate 4 (TSSC4) is a novel tumor suppressor that is upregulated in cancer cells contributing to sustainable cancer cell growth via autophagy inhibition.*
Yongqiang Chen, Zhaoying Zhang, Elizabeth S. Henson, Andrew Cuddihy, Katharina Haigh, Ruobing Wang, **Jody J. Haigh**, Spencer B. Gibson
Autophagy- 2021 September 17 [IF=16.02] {Citations=8}

95. *Reversible reprograming of cardiomyocytes to a fetal state drives adult heart regeneration in mice.* Chen, Y., Luttmann, F., **Haigh, J.J.**, Kim, J.#, Braun, T.#
Science-2021 Sept 24; 373(6562):1537-1540 [**IF=63.71**] **{Citations=66}**

94. Fetal hematopoietic stem cell homing is controlled by stromal VEGF regulating the integrity of the vascular niche and the oxidative status of the stromal-vascular bone marrow niches. Marion Mesnieres, Anna-Marei Böhm, Nicolas Peredo, Dana Trompet, Manmohan Bajaj, Nikky Corthout, Elena Nefyodova, Ruben Cardoen, Pieter Baatsen, Sebastian Muck, Andras Nagy, **Jody J. Haigh**, Satish Khurana, Catherine M. Verfaillie and Christa Maes
Cell Reports- 2021 August 24;36(8):109618 [**IF=10**] {Citations=5}

93. *A novel SARS-CoV-2 viral sequence tracking platform has found genetic evidence that the viral 3' untranslated region (UTR) is evolving and generating increased viral diversity.*
Carlos Farkas, Andy Mella, Maxime Turgeon, **Jody J. Haigh**
Frontiers in Microbiology-Virology- 12, 109618 [4.08] {Citations=14}

92. *CRISPR/Cas9 - The holy grail for generating biomedically relevant cells through cell fate engineering. (Review)* Vignesh Krishnamoorthy and **Jody J. Haigh**
Re:GEN Open, 2021 June 15 [IF=NA]

91. *Peripheral-specific Y1 receptor antagonist increases thermogenesis and protects against diet-induced obesity.* Chenxu Yan#, Tianshu Zeng#, Kailun Lee#, Max Nobis, Kim Loh, Luoning Gou, Zefeng Xia, Zhongmin Gao, Mohammed Bensellam, Will Hughes, Jackie Lau, Lei Zhang1, Chi 4 Kin Ip, Ronaldo Enriquez, Hanyu Gao,Qiao-Ping Wang, Qi Wu2, **Jody J Haigh**, D Ross Laybutt, Paul Timpson, Herbert Herzog#, Yan-Chuan Shi#
Nature Communications, 2021 May 11; 12**:**262 [**IF=17.69**] {Citations=27}

90. *Endothelial Zeb2 preserves the hepatic angioarchitecture and protects against liver fibrosis.*
Willeke de Haan, Wouter Dheedene, Eskeatnaf Mulugeta, Stefan Vinckier, Stefaan Verhulst, Andrea Conidi, Michael W. Staring, Petra Vandervoort, Ellen Caluwé, Marleen Lox, Inge Mannaerts, Tsuyoshi Takagi, Joris Jaekers, Geert Berx, **Jody J. Haigh**, Baki Topal, An Zwijsen, Yujiro Higashi, Leo A. van Grunsven, Wilfred F.J. Van IJcken, Danny Huylebroeck and Aernout Luttun
Cardiovascular Research- 2021 April 28 [**IF=10.79**] {Citations=11}

89*. Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2-dependent manner.*
Monika Gladka, Arwa Kohela, Bas Molenaar, Danielle Versteeg, Lieneke Kooijman, Harmjan Vos, Manon Huibers, **Jody Haigh**, Danny Huylebroeck, Mauro Giacca, Eva Van Rooij
Nature Communications 2021 Jan 4;12(1):84 [**IF=17.69**] {Citations=29}

2020

88. *TINC - a method to dissect transcriptional complexes at single locus resolution - reveals novel Nanog regulators in mouse embryonic stem cells.* AS Knaupp, M Mohenska, MR Larcombe, E Ford, SM Lim, K Wong, J Chen, J Firas, C Huang, X Liu, T Nguyen, YBY Sun, ML Holmes, P Tripathi, FJ Rossello, J Schröder, CM Nefzger, PP Das, **JJ Haigh**, R Lister, RB Schittenhelm, JM Polo
Stem Cell Reports Dec 2020 15(6): 1246-1259 [IF=7.77] {Citations=9}

87. *Insights on early mutational events in SARS-CoV-2 virus reveal founder effects across geographical regions.* Carlos Farkas, Francisco Fuentes-Villalobos, José Luis Garrido, **Jody J Haigh**, María Inés Barría
PeerJ DOI: 10.7717/peerj.9255 [IF=3.061] {Citations=30}

86. *Zeb2 drives invasive and microbiota-dependent colon carcinoma.* Karolina Lucja Slowicka, Ioanna Petta ,Gillian Blancke , Esther Hoste , Emilie Dumas , Mozes Sze , Hanna-Kaisa Vikkula , Konstantina Zafeiropoulou , Enrico Radaelli , **Jody J Haigh** , Sven Jonckheere , Joachim Taminau, Niels Vandamme , Andy Wullaert , Eugene Tulchinsky , David Nittner, Pieter Van Vlierberghe , Gert De Hertogh , Pamela Baldin , Hakki Emre Etlioglu , Pratyaksha Wirapati , Louis Boon , Bart

Lambrecht , Chris Callewaert , Sabine Tejpar , Steven Goossens, Geert Berx, Lars Vereecke, Geert van Loo
Nature Cancer, 2020 June 1:620–634 [**IF=23.18**] {Citations=26}

85. *The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.* Catherine L Carmichael#, Jueqiong Wang, Thao Nguyen, Aissa Benyoucef, Charlotte De Mazière, Anna Milne, Soroor Hediyeh-zadeh, Anh Vo, Yizhou Huang, Kathy Knezevic, William R L McInnes, Benjamin Shields, Helen Mitchell, Matthew E Ritchie, Katharina Haigh, Julie A I Thoms, Ethan P Oxley, Ross A Dickins, Dominik Beck, Andrew Perkins, Matthew McCormack, Melissa J Davis, Geert Berx, Johannes Zuber, John E Pimanda, Benjamin Kile, Steven Goossens# and **Jody J Haigh**#
Blood. 2020 Aug 20;136(8):957-973 [**IF=25.48**] {Citations=28}

84. *The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype.* Niels Vandamme, Geertrui Denecker, Kenneth Bruneel , Özden Akay , Gillian Blancke, Joachim Taminau, Eva De Smedt , Nicolas Skrypek , Mr. Wouter Van Loocke , Jasper Wouters , David Nittner , Corinna Köhler, Douglas Darling , Phil Cheng, Marieke Raaijmakers , Mitchell Levesque, Udupi Girish Mallya , Mairin Rafferty , Balazs Balint , William Gallagher , Lieve Brochez , Danny Huylebroeck , **Jody Haigh**, Pieter Van Vlierberghe, Steven Goossens, Joost van den Oord, Jean-Christophe Marine, Geert Berx
Cancer Research, 2020 June 5; 2983-2995 [**IF=12.7**] {Citations=36}

83. *Inactivation of Zeb1 in GRHL2-deficient mouse embryos rescues mid-gestation viability and secondary palate closure.* Carpinelli MR, de Vries ME, Auden A, Butt T, Deng Z, Partridge DD, Miles LB, Georgy SR, **Haigh JJ**, Darido C, Brabletz S, Brabletz T, Stemmler MP, Dworkin S, Jane SM.
Dis Model Mech 2020;13(3): dmm042218. [IF=5.73] {Citations=18}

2019

82. *Intestinal Neurod1 expression impairs paneth cell differentiation and promotes enteroendocrine lineage specification.* Li HJ, Ray SK, Pan N, **Haigh J**, Fritzsch B, Leiter AB.
Sci Rep 2019 Dec 20;9(1):19489. [IF=5.0] {Citations=16}

81. *Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies.* Pieters T, T'Sas S, Demoen L, Almeida A, Haenebalcke L, Matthijssens F, Lemeire K, D'Hont J, Van Rockeghem F, Hochepied T, Lintermans B, Reunes L, Lammens T, Berx G, **Haigh JJ**, Goossens S#, Van Vlierberghe P#.
Sci Rep. Jul 22;9(1):10577 [IF=5.0] {Citations=4}

80. *AIF-regulated oxidative phosphorylation supports lung cancer development.* Rao S, Mondragón L, Pranjic B, Hanada T, Stoll G, Köcher T, Zhang P, Jais A, Lercher A, Bergthaler A, Schramek D, Haigh K, Sica V, Leduc M, Modjtahedi N, Pai TP, Onji M, Uribesalgo I, Hanada R, Kozieradzki I, Koglgruber R, Cronin SJ, She Z, Quehenberger F, Popper H, Kenner L, **Haigh JJ**, Kepp O, Rak M, Cai K, Kroemer G, Penninger JM.
Cell Res. 29 (9) 579-591 **[IF=46.3] {Citations=51}**

79. *Modulating PKCα Activity to Target Wnt/β-Catenin Signaling in Colon Cancer.* Dupasquier S, Blache P, Picque Lasorsa L, Zhao H, Abraham JD, **Haigh JJ**, Ychou M, Prévostel C.
Cancers (Basel). May 18;11(5) 693 [IF=6.64] {Citations=26}

78. *GNrep mouse: A reporter mouse for front-rear cell polarity*. Barbacena P, Ouarné M, **Haigh JJ**, Vasconcelos FF, Pezzarossa A, Franco CA.
Genesis. 57(6): e23299 [IF=2.49] {Citations=6}

77. *ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms*. Goossens S, Wang J, Tremblay C, De Medts J, T'Sas S, Nguyen T, Saw J, Haigh K, Curtis DJ, Van Vlierberghe P, Berx G, Taghon T, **Haigh JJ**.
Haematologica. 2019 Aug;104(8):1608-1616. [**IF=11.04**] {Citations=16}

2018

76. *The pulmonary microvasculature entraps induced vascular progenitor cells (iVPCs) systemically delivered after cardiac ischemia-reperfusion injury: Indication for preservation of heart function via paracrine effects beyond engraftment.* Ziegler M, Haigh K, Nguyen T, Wang X, Lim B, Yap ML, Eddy EM, **Haigh JJ**[#], Peter K.[#]
Microcirculation. Jul 21: e12493 [IF=2.61] {Citations=11}

75. *Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.* Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, Del Monte-Nieto G, Adam ASA, Harvey RP, **Haigh JJ**, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP, Timpson P.
Cell Rep. Jun 12;23(11):3312-3326 [**IF=10**] **{Citations=54}**

74. *Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice*. Renard M, Vanhauwaert S, Vanhomwegen M, Rihani A, Vandamme N, Goossens S, Berx G, Van Vlierberghe P, **Haigh JJ,** Decaesteker B, Van Laere J, Lambertz I, Speleman F, Vandesompele J, Willaert A.
Sci Rep. May 16;8(1):7642 [IF=5.0] {Citations=13}

73. *A knock-in/knock-out mouse model of HSPB8-associated distal hereditary motor neuropathy and myopathy reveals toxic gain-of-function of mutant Hspb8.* Delphine Bouhy, Manisha Juneja, Istvan Katona, Anne Holmgren, Bob Asselbergh, Vicky De Winter, Tino Hochepied, Steven Goossens**, Jody J. Haigh**, Claude Libert, Chantal Ceuterick-de Groote, Joy Irobi, Joachim Weis, Vincent Timmerman
Acta Neuropathol, Jan;135(1):131-148 [**IF=17.09**] **{Citations=56}**

2017

72. *Platelet-Targeted Delivery of Peripheral Blood Mononuclear Cells to The Ischemic Heart Restores Cardiac Function After Ischemia-Reperfusion Injury*. Melanie Ziegler, Xiaowei Wang, Bock Lim, Ephraem Leitner, Franco Klingberg, Victoria Ching, Yu Yao, Dexing Huang, Xiao-Ming Gao, Helen Kiriazis, Xiao-Jun Du, **Jody J. Haigh**, Alex Bobik, Christoph E. Hagemeyer, Ingo Ahrens, Karlheinz Peter
Theranostics, Jul 22;7(13):3192-3206 [**IF=11.56**] {Citations=37}

71. Structure-function Studies in Mouse Embryonic Stem Cells Using Recombinase-mediated Cassette Exchange. Pieters, T., Haenebalcke, L., Bruneel, K., Vandamme, N., Hochepied, T., van Hengel, J., Wirth, D., Berx, G., **Haigh, J. J.**, Van Roy, F., Goossens, S.
Journal of Visualized Experiments (JOVE), Apr 27 Issue 122 [IF=1.4] {Citations=4}

70. *Zeb2 is essential for pluripotency exit and neural differentiation of mouse embryonic stem cells*. Stryjewska, A., Dries, R., Pieters, T., Verstappen, G., Conidi, A., Coddens, K., Umans, L., van Ijcken, W., van Grunsven, L.A., Goossens, S., **Haigh, J.J.**, Huylebroeck, D.
Stem Cells, March. 35(3): 611-625 [IF=6.28] **{Citations=45}**

69. *Oncogenic ZEB2 activation drives sensitivity towards LSD1 inhibition in T-cell acute lymphoblastic leukemia*. Steven Goossens[#], Sofie Peirs[#], Wouter Van Loocke, Mina Takawy, Stefan Sonderegger, Katharina Haigh, Thao Ngyuen, Niels Vandamme, Magdaline Costa, Catherine Carmichael, Filip Van Nieuwerburgh, Dieter Deforce, Oded Kleifeld, David Curtis, Geert Berx, Pieter Van Vlierberghe[*] and **Jody J. Haigh**[*]
Blood Journal, Feb 23. 129(8): 981-990 [**IF=25.48**] {Citations=25}

68. *Transitional B cells commit to marginal zone B cell fate by Taok3-mediated surface expression of ADAM10.* Hammad H, Vanderkerken M, Pouliot P, Deswarte K, Toussaint W, Vergote K, Vandersarren L, Janssens S, Ramou I, Savvides SN, **Haigh JJ**, Hendriks R, Kopf M, Craessaerts K, de Strooper B, Kearney JF, Conrad DH, Lambrecht BN
Nature Immunology, Feb 15. 18(3): 313-320 [**IF=31.25**] **{Citations=74}**

67. *Elevated ΔNp63α levels facilitate epidermal and biliary oncogenic transformation.* Devos, M., Gilbert, B., Denecker, G., Leurs, K., McGuire, C., Lemeire, K., Hochepied, T., Lambert, J., Van Den Broecke, C., Libbrecht, L., **Haigh, J.J.**, Berx, G., Lippens, S., Vandenabeele, P., Declercq, W.
Journal of Investigative Dermatology, Feb 1. 137(2): 494-505 [IF=8.55] {Citations=25}

66. *The Snail family in normal and malignant hematopoiesis*. Catherine Carmichael and **Jody J. Haigh**
Cells, Tissues, Organs (Review), Feb 1. 203(2): 82-98 [IF=2.48] {Citations=11}

65. *The EMT transcription factor controls adult murine hematopoietic differentiation by regulating cytokine signaling*. Li, J.[#], Goossens, S.[#], Riedt, T.[#], García, C.C., Dobrosch, L., Gütgemann, I., Radaelli, E., Fröhlich, H., Huylebroeck, D., Brossart, P., **Haigh, J.J.**, and Janzen V.
Blood Journal, Jan 26. 129(4): 460-472 [**IF=25.48**] **{Citations=49}**

2016

64. *p120 Catenin-Mediated Stabilization of E-cadherin is Essential for Primitive Endoderm Specification.* Tim Pieters, Steven Goossens, Lieven Haenebalcke,Vanessa Andries, Agata Stryjewska, Riet Derycke, Kelly Lemaire, Tino Hochepied, Danny Huylebroeck, Geert Berx, Marc Stemmler, Dagmar Wirth, **Jody J. Haigh**, Frans Van Roy*, Jolanda Van Hengel*.
PLOS Genetics, Aug 24. 12(8):1-28 [IF=6.02] {Citations=30}

63. *Characterization of new transgenic mouse models for two Charcot-Marie-Tooth-causing HspB1 mutations using the Rosa26 locus.* Delphine Bouhy, Thomas Geuens, Vicky De Winter, Leonardo De Almeida Souza, Istvan Katona, Joachim Weis, Tino Hochepied, Steven Goossens, **Jody J. Haigh**, Sophie Janssens, Vincent Timmerman
Journal of Neuromuscular Diseases, May 27. 3(2): 183-200 [IF=4.44} {Citations=16}

62. *LIN28 is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19.* Helsmoortel HH, De Moerloose B, Pieters T, Ghazavi F, Bresolin S, Cave' H, de Vries A, de Haas V, Flotho C, Labarque V, Niemeyer C, De Paepe P, Van Roy N, Stary J, van den Heuvel-Eibrink MM, Benoit Y, Schulte J, Goossens S, Berx G, **Haigh JJ**, Speleman F, Van Vlierberghe P, Lammens T.
Haematologica Jun. 101(6):e240-4 [**IF=11.04**] {Citations=20}

61. *PTP1B deficiency enables the ability of a high fat diet to drive the invasive character of PTEN-deficient prostate cancers.* Labbé, D.P., Uetani, N., Vinette, V., Aubry, I., Migon, E., Sirois, J., **Haigh, J. J.**, Lessard, L., Bégin, L.R., Trotman, L.C., Paquet, M., Tremblay, M.L.
Cancer Res Jun 1. 76 (11): 3130-5 [**IF=12.7**] {Citations=20}

60. *The transcription factor Zeb2 regulates development of conventional and plasmacytoid DCs.* Charlotte Scott, Bieke Soen, Liesbet Martens, Nicolas Skrypek, Wouter Saelens, Joachim Taminau, Gillian Blancke, Gert Van Isterdael, Danny Huylebroeck, **Jody J. Haigh**, Yvan Saeys, Martin Guilliams, Bart Lambrecht, and Geert Berx.
JEM May 30. 213(6): 897-911 [**IF=17.58**] **{Citations=131}**

2015

59. *Terminal NK cell maturation is controlled by concerted actions of T-Bet and Zeb2 and is essential for melanoma rejection.* Van Helden#, M., Goossens#, S., Daussy#, C., Debaud, A.L., Faure, F., Marçais, A., Vandamme, N., Mayol, K., Viel, S., Degouve, S., Debien, E., Seuntjens, E., Conidi, A., Chaix, J., Mangeot, P., de Bernard, S., Buffat, L., **Haigh, J.J.**, Lambrecht, B., Huylebroeck, D., Berx, G., and Walzer T.
JEM Nov 16; 212(12):2015-25 [**IF=17.58**] **{Citations=144}**

58. *Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection.* Omilusik, K.D., Best, J.A., Yu, B., Nguyen, J.V., Goossens, S., Seuntjens, E., Weidemann, A., Zweier, C., Bird, L., Kondoh, H., Huylebroeck, D., **Haigh, J.J.**, Goldrath, A.W.
JEM Nov 16; 212(12):2027-39 [**IF=17.58**] **{Citations=156}**

57. *Novel biological insights in T-cell acute lymphoblastic leukemia*. Durinck K, Goossens S, Peirs S, Wallaert A, Van Loocke W, Matthijssens F, Pieters T, Milani G, Lammens T, Rondou P, Van Roy N, De Moerloose B, Benoit Y, **Haigh J**, Speleman F, Poppe B, Van Vlierberghe P.
Exp Hematol 2015 Aug;43(8):625-39. (Review) [IF=3.08] **{Citations=116}**

56. *Muller glia are a major cellular source of survival signals for retinal neurons in diabetes*. Fu, S., Dong, S., Zhu, M., Sherry D.M., Wang, C., You, Z., **Haigh, J.J.**, Le, Y.Z.
Diabetes, Oct;64(10):3554-63 **[IF=9.34] {Citations=84}**

55. *Strategies to Rescue the Lethal Consequences of Inducible Arginase-1 Deficiency in Mice*. Ballantyne, L. L., Yan Sin, Y., St. Amand, T., Si, J., Goossens, S., Haenebalcke, L., **Haigh, J. J.**, Schulze, A., Funk, C.D.
PLOS One,10(5):e0125967 [IF=3.75] {Citations=11}

54. *Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression*. Martin, A., Salvador, F., Floristán, A., Moreno-Bueno, G., Morales, S., Santos, V., Csiszar, K., Dubus, P., **Haigh, J.J.**, Portillo, F., Cano A.
EMBO J, 34(8):1090-109 **[IF=13.78] {Citations=86}**

53. *Snai1 regulates cell lineage allocation and stem cell maintenance in the mouse intestinal epithelium.* Horvay, K., Jarde, T., Casagranda F., Perreau V.M., Haigh, K., Gridley, T., Berx, G., **Haigh, J.J.**, Barker, N., Polo, J.M., Hime, G.R., Abud, H.E.
EMBO J, 12;34(10):1319-35 **[IF=13.78] {Citations=54}**

52. *ER-directed gelsolin nanobody establishes therapeutic merit in the gelsolin amyloidosis mouse model by shielding mutant plasma gelsolin from furin proteolysis.*
Van Overbeke, W., Wongsantichon, J., Everaert, I., Verhelle, A., Zwaenepoel, O., De Ganck, A., Hochepied, T., **Haigh, J.J.**, Cuvelier, C., Derave, W., Robinson, R., Gettemans, J.
Hum Mol Genet 24(9):2492-507 [IF=6.15] **{Citations=52}**

51. *ZEB2 drives immature T-cell lymphoblastic leukemia development via altered IL-7 receptor signalling and enhanced tumor-initiating potential*. Goossens, S., Radaelli, E., Blanchet, O., Durinck, K., Van der Meulen, J., Peirs, S., Taghon, T., Tremblay, C., Costa, M., Farhang Ghahremani, M., De Medts, J., Bartunkova, S., Haigh, K., Schwab, C., Farla, N., Pieters, T., Matthijssens, F., Van Roy, N., Best, J.A., Deswarte, K., Bogaert, P., Carmichael, C., Rickard, A., Suryani, S., Bracken, L.S., Alserihi, R., Canté-Barrett, K., Haenebalcke, L., Clappier, E., Rondou, P., Slowicka, K., Huylebroeck, D., Goldrath, A.W., Janzen, V., McCormack, M.P., Lock, R.B., Curtis, D.J., Harrison, C., Berx, G., Speleman, F., Meijerink, J.P.P., Soulier, J., Van Vlierberghe, P. and **Haigh, J.J.**
Nature Communications, Jan 7; 6: 5794 [**IF=17.69**] **{Citations=87}**

2014

50. *Immunohistological Description of Nongestational Ovarian Choriocarcinoma in Two Female Mice With Conditional Loss of Trp53 Driven by the Tie2 Promoter.* Castiglioni V, Ghahremani MF, Goossens S, De Maglie M, Ardizzone M, **Haigh JJ**, Radaelli E.
Vet Pathol. 52(4):752-6 [IF=2.11] {Citations=4}

49. *Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression*. Denecker, G., Vandamme, N., Akay, O., Koludrovic, D., Taminau, J., Lemeire, K., Gheldof, A., De Craene, B., Van Gele, M., Brochez, L. Udupi, G., Rafferty, M., Balint, B., Gallagher, W., Ghanem, G., Huylebroeck, D., **Haigh, J.J.**, van den Oord, J., Larue, L., Davidson, I., Marine, J.C. Berx G.
Cell Death Differ 21(8):1250-61 **[IF=12.07] {Citations=199}**

48. *Loss of autocrine endothelial-derived VEGF significantly reduces hemangiosarcoma development in conditional p53-deficient mice*. Farhang Ghahremani, M., Radaelli, E., Haigh, K., Bartunkova, S. Haenebalcke, L., Marine, J.C. Goossens, S., **Haigh, J.J.**
Cell Cycle (2014) May 1;13(9):1501-7 [IF=4.31] {Citations=12}

47. *ZEB2-transgene expression in the epidermis compromises the integrity of the epidermal barrier through the repression of different tight junction proteins.* Tatari MN, De Craene B, Soen B, Taminau J, Vermassen P, Goossens S, Haigh K, Cazzola S, Lambert J, Huylebroeck D, **Haigh J.J.**, Berx, G.
Cell Mol Life Sci 71(18):3599-609 **[IF=9.78]** {Citations=27}

2013

46. *Beta-Actin Is Involved in Modulating Erythropoiesis during Development by Fine-Tuning Gata2 Expression Levels*. Tondeleir, D.; Drogat, B.; Slowicka, K.; Bakkali, K.; Bartunkova, S.; Goossens, S.; **Haigh, J. J.** #, Ampe, C. #
PloS one 8 6 e67855 [IF=3.75] {Citations=16}

45. *Directed migration of cortical interneurons depends on the cell-autonomous action of Sip1.* van den Berghe, V.; Stappers, E.; Vandesande, B.; Dimidschstein, J.; Kroes, R.; Francis, A.; Conidi, A.; Lesage, F.; Dries, R.; Cazzola, S.; Berx, G.; Kessaris, N.; Vanderhaeghen, P.; van Ijcken, W.; Grosveld, F. G.; Goossens, S.; **Haigh, J. J.**; Fishell, G.; Goffinet, A.; Aerts, S.; Huylebroeck, D.; Seuntjens, E.
Neuron 77 1 70-82 **[IF=18.69] {Citations=121}**

44. *Efficient ROSA26-Based Conditional and/or Inducible Transgenesis Using RMCE-Compatible F1 Hybrid Mouse Embryonic Stem Cells*. Haenebalcke, L.; Goossens, S.; Naessens, M.; Kruse, N.; Ghahremani, M. F.; Bartunkova, S.; Haigh, K.; Pieters, T.; Dierickx, P.; Drogat, B.; Nyabi, O.; Wirth, D.; **Haigh, J. J.**
Stem Cell Rev 9(6):774-85 [IF=6.69] **{Citations=41}**

43. *Endothelial VEGF Sculpts Cortical Cytoarchitecture*. Li, S.; Haigh, K. **Haigh, J.J.** #; Vasudevan, A#.
J Neurosci 33 37 14809-14815 [IF=6.71] **{Citations=57}**

42. *Gata3 antagonizes cancer progression in Pten-deficient prostates.* Nguyen, A. H.; Tremblay, M.; Haigh, K.; Koumakpayi, I. H.; Paquet, M.; Pandolfi, P. P.; Mes-Masson, A. M.; Saad, F.; **Haigh, J. J.**; Bouchard, M.
Hum Mol Genet 15;22(12):2400-10 [IF=6.15] **{Citations=41}**

41. *Identification of a clonally expanding haematopoietic compartment in bone marrow.* Wang, L.; Benedito, R.; Bixel, M. G.; Zeuschner, D.; Stehling, M.; Savendahl, L.; **Haigh, J. J.;** Snippert, H.; Clevers, H.; Breier, G.; Kiefer, F.; Adams, R. H.
EMBO J 32 2 219-30 **[IF=13.78] {Citations=80}**

40. *Mice Overexpressing β-1,4-Galactosyltransferase I Are Resistant to TNF-Induced Inflammation and DSS-Induced Colitis*. Vanhooren V, Vandenbroucke RE, Dewaele S, Van Hamme E, **Haigh JJ**, Hochepied T, Libert C.
Plos One 8 12 e79883 [IF=3.75] {Citations=14}

39. *The ROSA26-iPSC mouse: a conditional, inducible, and exchangeable resource for studying cellular (De)differentiation*. Haenebalcke, L.; Goossens, S.; Dierickx, P.; Bartunkova, S.; D'Hont, J.; Haigh, K.; Hochepied, T.; Wirth, D.; Nagy, A.; **Haigh, J. J.**
Cell Rep 3 2 335-41 **[IF=10] {Citations=44}**

38. *The p53 family and VEGF regulation: "It's complicated"*. Farhang Ghahremani, M.; Goossens, S.; **Haigh, J. J.**
Cell Cycle 12 9 1331-2 (Review) [IF=4.3] **{Citations=47}**

37. *p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway.* Farhang Ghahremani, M.; Goossens, S.; Nittner, D.; Bisteau, X.; Bartunkova, S.; Zwolinska, A.; Hulpiau, P.; Haigh, K.; Haenebalcke, L.; Drogat, B.; Jochemsen, A.; Roger, P. P.; Marine, J. C.; **Haigh, J. J.**
Cell Death Differ 20 7 888-97 **[IF=12.07] {Citations=100}**

2012

36. *Efficient and user-friendly pluripotin-based derivation of mouse embryonic stem cells*. Pieters, T.; Haenebalcke, L.; Hochepied, T.; D'Hont, J.; **Haigh, J. J.**; van Roy, F.; van Hengel, J.
Stem Cell Rev 8 3 768-78 [IF=6.69] {Citations=22}

35. *Formation of the collateral circulation is regulated by vascular endothelial growth factor-A and a disintegrin and metalloprotease family members 10 and 17*. Lucitti, J. L.; Mackey, J. K.; Morrison, J. C.; **Haigh, J. J.**; Adams, R. H.; Faber, J. E.
Circ Res 111 12 1539-50 **[IF=23.21] {Citations=111}**

34. *MDM4 is a key therapeutic target in cutaneous melanoma*. Gembarska, A.; Luciani, F.; Fedele, C.; Russell, E. A.; Dewaele, M.; Villar, S.; Zwolinska, A.; Haupt, S.; de Lange, J.; Yip, D.; Goydos, J.; **Haigh, J. J.;** Haupt, Y.; Larue, L.; Jochemsen, A.; Shi, H.; Moriceau, G.; Lo, R. S.; Ghanem, G.; Shackleton, M.; Bernal, F.; Marine, J. C.
Nature Medicine 18(8):1239-47 **[IF=87.24] {Citations=337}**

***33.** *Opposing roles for Hoxa2 and Hoxb2 in hindbrain oligodendrocyte patterning.* Miguez, A.; Ducret, S.; Di Meglio, T.; Parras, C.; Hmidan, H.; Haton, C.; Sekizar, S.; Mannioui, A.; Vidal, M.; Kerever, A.; Nyabi, O.; **Haigh, J.;** Zalc, B.; Rijli, F. M.; Thomas, J. L.
J Neurosci 32 48 17172-85 [IF=6.71] {Citations=35}

32. *Tissue-wide overexpression of alpha-T-catenin results in aberrant trophoblast invasion but does not cause embryonic mortality in mice.* Tyberghein, K.; Goossens, S.; **Haigh, J. J.**; van Roy, F.; van Hengel, J.
Placenta 33 7 554-60 [IF=3.41] {Citations=15}

***31.** *VEGF-independent cell-autonomous functions of HIF-1alpha regulating oxygen consumption in fetal cartilage are critical for chondrocyte survival.* Maes, C.; Araldi, E.; Haigh, K.; Khatri, R.; Van Looveren, R.; Giaccia, A. J.; **Haigh, J. J.**; Carmeliet, G.; Schipani, E.
J Bone Miner Res 27 3 596-609 [IF=6.44] **{Citations=96}**

2011

30. *A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.* Beck, B.; Driessens, G.; Goossens, S.; Youssef, K. K.; Kuchnio, A.; Caauwe, A.; Sotiropoulou, P. A.; Loges, S.; Lapouge, G.; Candi, A.; Mascre, G.; Drogat, B.; Dekoninck, S.; **Haigh, J. J.;** Carmeliet, P.; Blanpain, C.
Nature 478 7369 399-403. **[IF=69.5] {Citations=484}**

29. *Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons.* Dhondt, J.; Peeraer, E.; Verheyen, A.; Nuydens, R.; Buysschaert, I.; Poesen, K.; Van Geyte, K.; Beerens, M.; Shibuya, M.; **Haigh, J. J.**; Meert, T.; Carmeliet, P.; Lambrechts, D.
Faseb J 25 5 1461-73 [IF=5.02] **{Citations=62}**

28. *The EMT regulator Zeb2/Sip1 is essential for murine embryonic hematopoietic stem/progenitor cell differentiation and mobilization.* Goossens, S.; Janzen, V.; Bartunkova, S.; Yokomizo, T.; Drogat, B.; Crisan, M.; Haigh, K.; Seuntjens, E.; Umans, L.; Riedt, T.; Bogaert, P.; Haenebalcke, L.; Berx, G.; Dzierzak, E.; Huylebroeck, D.; **Haigh, J. J.**
Blood 117 21 5620-30. [**IF=25.48**] **{Citations=99}**

27. *VEGF mediates commissural axon chemoattraction through its receptor Flk1.* Ruiz de Almodovar, C.; Fabre, P. J.; Knevels, E.; Coulon, C.; Segura, I.; Haddick, P. C.; Aerts, L.; Delattin, N.; Strasser, G.; Oh, W. J.; Lange, C.; Vinckier, S.; **Haigh, J.**; Fouquet, C.; Gu, C.; Alitalo, K.; Castellani, V.; Tessier-Lavigne, M.; Chedotal, A.; Charron, F.; Carmeliet, P.
Neuron 70 5 966-78 **[IF=18.69] {Citations=162}**

2010

26. *Identification of a co-activator that links growth factor signalling to c-Jun/AP-1 activation.* Davies, C. C.; Chakraborty, A.; Cipriani, F.; Haigh, K.; **Haigh, J. J.**; Behrens, A.
Nat Cell Biol 12 10 963-72 **[IF=28.21] {Citations=48}**

25. *Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery.* Storkebaum, E.; Ruiz de Almodovar, C.; Meens, M.; Zacchigna, S.; Mazzone, M.; Vanhoutte, G.; Vinckier, S.; Miskiewicz, K.;

Poesen, K.; Lambrechts, D.; Janssen, G. M.; Fazzi, G. E.; Verstreken, P.; **Haigh, J.**; Schiffers, P. M.; Rohrer, H.; Van der Linden, A.; De Mey, J. G.; Carmeliet, P.
Circulation 122 3 273-81 **[IF=39.92] {Citations=42}**

24. *Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones.* Maes, C.[#]; Goossens, S.[#]; Bartunkova, S[#].; Drogat, B.; Coenegrachts, L.; Stockmans, I.; Moermans, K.; Nyabi, O.; Haigh, K.; Naessens, M.; Haenebalcke, L.; Tuckermann, J. P.; Tjwa, M.; Carmeliet, P.; Mandic, V.; David, J. P.; Behrens, A.; Nagy, A.; Carmeliet, G.; **Haigh, J. J.**
EMBO J 29 2 424-41 **[IF=13.78] {Citations=200}**

23. *Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1.* Ruiz de Almodovar, C.; Coulon, C.; Salin, P. A.; Knevels, E.; Chounlamountri, N.; Poesen, K.; Hermans, K.; Lambrechts, D.; Van Geyte, K.; Dhondt, J.; Dresselaers, T.; Renaud, J.; Aragones, J.; Zacchigna, S.; Geudens, I.; Gall, D.; Stroobants, S.; Mutin, M.; Dassonville, K.; Storkebaum, E.; Jordan, B. F.; Eriksson, U.; Moons, L.; D'Hooge, R.; **Haigh, J. J.**; Belin, M. F.; Schiffmann, S.; Van Hecke, P.; Gallez, B.; Vinckier, S.; Chedotal, A.; Honnorat, J.; Thomasset, N.; Carmeliet, P.; Meissirel, C.
J Neurosci 30 45 15052-66 {IF=6.71] **{Citations=89}**

22. *VEGFR2 (KDR/Flk1) signaling mediates axon growth in response to semaphorin 3E in the developing brain.* Bellon, A.; Luchino, J.; Haigh, K.; Rougon, G.; **Haigh, J.**; Chauvet, S.; Mann, F.
Neuron 66 2 205-19 **[IF=18.69] {Citations=143}**

21. *Vegf regulates embryonic erythroid development through Gata1 modulation.* Drogat, B.; Kalucka, J.; Gutierrez, L.; Hammad, H.; Goossens, S.; Farhang Ghahremani, M.; Bartunkova, S.; Haigh, K.; Deswarte, K.; Nyabi, O.; Naessens, M.; Ferrara, N.; Klingmuller, U.; Lambrecht, B. N.; Nagy, A.; Philipsen, S.; **Haigh, J.**
Blood 116 12 2141-51 [**IF=25.48**] {Citations=25}

20. *Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.* De Clercq, S.; Gembarska, A.; Denecker, G.; Maetens, M.; Naessens, M.; Haigh, K.; **Haigh, J. J.**; Marine, J. C.
Mol Cell Biol 30 22 5394-405 [IF=5.07] **{Citations=46}**

2005-2009

19. *Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells.* Nyabi, O.; Naessens, M.; Haigh, K.; Gembarska, A.; Goossens, S.; Maetens, M.; De Clercq, S.; Drogat, B.; Haenebalcke, L.; Bartunkova, S.; De Vos, I.; De Craene, B.; Karimi, M.; Berx, G.; Nagy, A.; Hilson, P.; Marine, J. C.; **Haigh, J. J.**
Nucleic Acids Res 37 7 e55 (2009) **[IF=19.16] {Citations=118}**

18. *Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling.* Parsa, S.; Ramasamy, S. K.; De Langhe, S.; Gupte, V. V.; **Haigh, J. J.**; Medina, D.; Bellusci, S.
Dev Biol 317 1 121-31 (2008) [IF=3.58] **{Citations=126}**

17. *Role of VEGF in organogenesis*. **Haigh, J. J.**
Organogenesis 4 4 247-5 (2008) (Review) [IF=2.5] **{Citations=107}**

16. *Developmental and adult phenotyping directly from mutant embryonic stem cells.* George, S. H.; Gertsenstein, M.; Vintersten, K.; Korets-Smith, E.; Murphy, J.; Stevens, M. E.; **Haigh, J. J.**; Nagy, A.
Proc Natl Acad Sci U S A 104 11 4455- 60 (2007) **[IF=12.78] {Citations=200}**

15. *Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia*. Cervi, D.; Shaked, Y.; Haeri, M.; Usenko, T.; Lee, C. R.; **Haigh, J. J.**; Nagy, A.; Kerbel, R. S.; Yefenof, E.; Ben-David, Y.
Blood 109 5 2139-46 (2007) [**IF=25.48**] {Citations=26}

14. *Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis.* Ahmad, S.; Hewett, P. W.; Wang, P.; Al-Ani, B.; Cudmore, M.; Fujisawa, T.; Haigh, J. J.; le Noble, F.; Wang, L.; Mukhopadhyay, D.; Ahmed, A.
Circ Res 99 7 715-22 (2006) **[IF=23.21] {Citations=170}**

13. *Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival*. Eremina, V.; Cui, S.; Gerber, H.; Ferrara, N.; **Haigh, J.**; Nagy, A.; Ema, M.; Rossant, J.; Jothy, S.; Miner, J. H.; Quaggin, S. E.
J Am Soc Nephrol 17 3 724-35 (2006) **[IF=14.98] {Citations=261}**

12. *Vascular endothelial growth factor directly inhibits primitive neural stem cell survival but promotes definitive neural stem cell survival*. Wada, T.; **Haigh, J.** J.; Ema, M.; Hitoshi, S.; Chaddah, R.; Rossant, J.; Nagy, A.; van der Kooy, D.
J Neurosci 26 25 6803-12 (2006) [IF=6.71] **{Citations=137}**

11. *Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction*. Belteki, G#.; **Haigh, J.#**; Kabacs, N.; Haigh, K.; Sison, K.; Costantini, F.; Whitsett, J.; Quaggin, S. E.; Nagy, A.# co-first authorship
Nucleic Acids Res 33 5 e51 (2005) **[IF=19.16] {Citations=386}**

1994-2004

10. *Activated Fps/Fes partially rescues the in vivo developmental potential of Flk1-deficient vascular progenitor cells.* **Haigh, J. J.**; Ema, M.; Haigh, K.; Gertsenstein, M.; Greer, P.; Rossant, J.; Nagy, A.; Wagner, E. F.
Blood 103 3 912-20 (2004) [**IF=25.48**] {Citations=18}

9. *Cre recombinase specificity defined by the tau locus*. Korets-Smith, E.; Lindemann, L.; Tucker, K. L.; Jiang, C.; Kabacs, N.; Belteki, G.; **Haigh, J.**; Gertsenstein, M.; Nagy, A.
Genesis 40 3 131-8 (2004) [IF=2.49] {Citations=21}

8. *Loss of vascular endothelial growth factor-a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation.* Rossiter, H.; Barresi, C.; Pammer, J.; Rendl, M.; **Haigh, J.**; Wagner, E. F.; Tschachler, E.

Cancer Res 64 10 3508-16 (2004) **[IF=12.7] {Citations=137}**

7. *Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling.* **Haigh, J.** J.; Morelli, P. I.; Gerhardt, H.; Haigh, K.; Tsien, J.; Damert, A.; Miquerol, L.; Muhlner, U.; Klein, R.; Ferrara, N.; Wagner, E. F.; Betsholtz, C.; Nagy, A.
Dev Biol 262 2 225- 41 (2003) [IF=3.58] **{Citations=301}**

6. *Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.* Eremina, V.; Sood, M.; **Haigh, J.**; Nagy, A.; Lajoie, G.; Ferrara, N.; Gerber, H. P.; Kikkawa, Y.; Miner, J. H.; Quaggin, S. E.
J Clin Invest 111 5 707-16. (2003) **[IF=19.46] {Citations=1467}**

5. *Impaired intervertebral disc formation in the absence of Jun.* Behrens, A.; **Haigh, J.**; Mechta-Grigoriou, F.; Nagy, A.; Yaniv, M.; Wagner, E. F.
Development 130 1 103-9 (2003) [IF=6.86] **{Citations=93}**

4. *Hyperglycemia-induced vasculopathy in the murine conceptus is mediated via reductions of VEGF-A expression and VEGF receptor activation.* Pinter, E.; **Haigh, J.**; Nagy, A.; Madri, J. A.
Am J Pathol 158 4 1199-206 (2001) [IF=5.48] **{Citations=93}**

3. *Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state.* **Haigh, J. J.**; Gerber, H. P.; Ferrara, N.; Wagner, E. F.
Development 127 7 (2000) [IF=6.86] **{Citations=243}**

2. *The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans- golgi network.* **Haigh, J.;** McVeigh, J.; Greer, P.
Cell Growth Differ 7 7 931-44 (1996) [IF=3.063] **{Citations=104}**

1. *The Fps/Fes protein-tyrosine kinase promotes angiogenesis in transgenic mice.* Greer, P.; **Haigh, J.**; Mbamalu, G.; Khoo, W.; Bernstein, A.; Pawson, T.
Mol Cell Biol 14 10 6755-63 (1994) [IF=5.07] **{Citations=120}**

Book Chapters

5. *Cre/lox – Transgenics.* Haenebalcke L, **Haigh J.J.** Brenner's Encyclopedia of Genetics (Second Edition) (2013)

4. *The role of EMT modulators in hematopoiesis and leukemic transformation.* Goossens, S., **Haigh J.J.**
Hematology - Science and Practice (2012)

3. *The Role of VEGF-A in organogenesis VEGF and Development.* **Haigh, J.J.** (2008) *Chapter 5: VEGF and Development.* Editor: Christiana Ruhrberg, Landes Bioscience.

2. Angiogenesis: Basic Science and Clinical Aspects **Haigh, J.J.**, Ruiz de Almodovar, C., Schneider, M., Carmeliet, P. Chapter 7: *From Basic Science to Clinical Applications.* Editor: Napoleone Ferrara, CRC Press, 2006.

1. *Whole mount analysis of the embryonic vasculature.* **Haigh, J.J.**, Nagy, A. Methods in Endothelial Cell Biology (2004) Chapter 27: Editor: Helmut G. Augustin, Springer-Verlag Berlin Heidelberg New York.

Published Meeting Abstracts:

31. ZEB2 and LMO2 Drive Immature T-Cell Lymphoblastic Leukemia Via Distinct Oncogenic Mechanisms
S Goossens, J Wang, C Tremblay, P Van Vlierberghe, G Berx, T Taghon, ...
Blood 132 (Supplement 1), 3916-3916, 2018

30. Abstract A08: Fast and efficient generation of conditional ROSA26-based mouse models that recapitulate oncogene activation in T-cell acute lymphoblastic leukemia
T Pieters, S TSas, B Lintermans, S Peirs, F Mathijssens, **J Haigh**, G Berx, ...
Cancer Research 78 (10 Supplement), A08-A08, 2018

29. Fast and efficient generation of conditional ROSA26-based mouse models that recapitulate oncogene activation in T-cell acute lymphoblastic leukemia.
T Pieters, S Tsas, B Lintermans, S Peirs, F Mathijssens, **J Haigh**, G Berx, ...
CANCER RESEARCH 78 (10), 34-34, 2018

28. CYCLIN D2 OVEREXPRESSION RECAPITULATES MANTLE CELL LYMPHOMA IN MICE
T Pieters, S T'Sas, J Morscio, F Matthijssens, K Lemeire, T Hochepied, B Lintermans, L Reunes, G Berx, **J Haigh**, S Goossens, P Van Vlierberghe
ASH Meeting Abstract
HAEMATOLOGICA 102, 558-559, 2017

27. THERAPEUTIC TARGETING OF ONCOGENIC MYB ACTIVITY IN T-ALL
T Pieters, S T'Sas, J Morscio, F Matthijssens, K Lemeire, T Hochepied, B Lintermans, L Reunes, **J Haigh**, G Berx, S Goossens, P Van Vlierberghe
ASH Meeting Abstract
HAEMATOLOGICA 102, 158-158, 2017

26. Oncogenic ZEB2 Activation Drives Sensitivity Towards LSD1 Inhibition in T-Cell Acute Lymphoblastic Leukemia
S Goossens, S Peirs, G Berx, P Van Vlierberghe, **JJ Haigh**
ASH meeting Abstract
Blood 128 (22), 4027-4027, 2016

25. The EMT Modulator SNAI1 Drives AML Development Via Its Interaction with the Chromatin Modulator LSD1

Catherine L Carmichael, Steven Goossens, Jueqiong Wang, Thao Nguyen, Katharina Haigh, Geert Berx, Benjamin Kile, **Jody J Haigh**
ASH meeting abstract
Blood 128 (22), 2688-2688, 2016

24. FAST GENERATION OF CONDITIONAL ROSA26-BASED MOUSE MODELS THAT RECAPITULATE GENOMIC EVENTS IN HUMAN T-ALL
T Pieters, S Goossens, S T'Sas, L Haenebalcke, T Hochepied, ...
21st Congress of the European-Hematology-Association 101, 322-322, 2016

23. Abstract B39: PTP1B deficiency potentiate prostate cancer invasiveness by sensitizing Pten-null tumors to high-fat diet
DP Labbé, N Uetani, V Vinette, I Aubry, E Migon, J Sirois, **JJ Haigh**, ...
Molecular Cancer Research 14 (1 Supplement), B39-B39, 2016

22. Zeb2 loss in adult mice results in a myeloproliferative disorder and is associated with altered JAK/STAT signaling pathway
J Li, T Riedt, S Goossens, I Guetgemann, D Huylebroeck, **J Haigh**, ...
Oncology Research and Treatment 38, 228-228, 2015

21. ZEB2 drives immature t-cell lymphoblastic leukemia development via enhanced tumor initiating potential and increased IL-7 receptor signaling
JJ Haigh, S Goossens
ISEH Meeting Abstract
Experimental Hematology 43 (9), S106, 2015

20. A novel role for the EMT regulator, snai1, in hematopoiesis and leukemia
C Carmichael, S Goossens, B Kile, **JJ Haigh**
ISEH Meeting Abstract
Experimental Hematology 43 (9), S56, 2015

19. Identification of a ZEB2-ZEB1-MITF transcriptional network that controls melanogenesis and melanoma progression
Geertrui Denecker, Niels Vandamme, Oezden Akay, Bram De Craene, Lieve Brochez, Joost van den Oord, William Gallagher, Ghanem Ghanem, Lionel Larue, **Jody Haigh**, Irwin Davidson, Jean-Christophe Marine, Geert Berx
CLINICAL & EXPERIMENTAL METASTASIS 32 (3), 194-195, 2015

18. Delta Np63 alpha drives mutagen-induced skin tumor initiation and progression to malignancy
M Devos, G Denecker, B Gilbert, K Leurs, K Lemeire, T Hochepied, **J Haigh**, G Berx, S Lippens, P Vandenabeele, W Declercq.
JOURNAL OF INVESTIGATIVE DERMATOLOGY 133, S67-S67, 2013

17. Zeb2-Defficiency in the Adult Murine Hematopoietic Precursor Cells Leads to Differentiation Defects in Multiple Hematopoietic Lineages and a Myeloproliferative-Like Phenotype

Tamara Riedt, Steven Goossens, Ines Gütgemann, Carmen Carrillo-Garcia, Hichem D Gallala, Holger Fröhlich, Peter Brossart, Dany Huylebroeck, **Jody J Haigh**, Viktor Janzen
ASH meeting Abstract
Blood 120 (21), 1199-1199, 2012

16. The Emt transcription factor Zeb2 plays a major role in melanogenesis and metastatic melanoma
G Denecker, N Vandamme, J Taminau, K Lemeire, A Gheldof, B De Craene, M Van Gele, L Brochez, M Rafferty, GM Udupi, B Balint, W Gallagher, L Larue, **J Haigh**, C Marine, G Berx
Pigment Cell & Melanoma Research 25 (6), 851, 2012

15. Mdm4 is a key therapeutic target in melanoma
A Gembarska, F Luciani, J de Lange, A Zwolinska, D Yip, J Goydos, **J Haigh**, L Larue, A Jochemsen, G Ghanem, F Bernal, C Marine
Pigment Cell & Melanoma Research 25 (6), 858, 2012

14. The EMT regulator Zeb2 is essential for adult hematopoietic stem and progenitor cell differentiation
T Riedt, S Goossens, I Guetgemann, C Carrillo-Garcia, H Gallala, M Dotten, **J Haigh**, P Brossart, V Janzen
ONKOLOGIE 35, 20-20, 2012

13. DeltaNp63alpha drives mutagen-induced skin tumor initiation and progression to malignancy
M Devos, G Denecker, S Lippens, B Gilbert, K Leurs, T Hochepied, H van Bokhoven, **J Haigh**, P Vandenabeele, W Declercq
JOURNAL OF INVESTIGATIVE DERMATOLOGY 132, S39-S39, 2012

12. Mdmx is a key therapeutic target in melanoma
A Gembarska, F Luciani, J de Lange, A Zwolinska, D Yip, J Goydos, **J Haigh**, L Larue, A Jochemsen, G Ghanem, F Bernal, J-c Marine
Pigment Cell & Melanoma Research 24 (5), 1016-1017, 2011

11. HIF-1a and VEGF promote chondrocyte survival via complementary mechanisms regulating the oxygen level in the avascular developing growth cartilage
Christa Maes, E Araldi, K Haigh, R Khatri, Riet Van Looveren, AJ Giaccia, **JJ Haigh**, Geert Carmeliet, Ernestina Schipani
Bone 48, S68, 2011

10. THE EMT INDUCER SIP1/ZEB2 IS ESSENTIAL FOR DEFINITIVE EMBRYONIC HEMATOPOIESIS
S Goossens, T Yokomizo, B Drogat, S Bartunkova, K Haigh, E Seuntjens, M Crisan, T Riedt, G Berx, E Dzierzak, V Janzen, D Huylebroeck**, J Haigh**
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 95, 478-478, 2010

9. Over-expression of Specific VEGF Isoforms Differentially Enhances and Patterns Bone Formation by Modulating Angiogenesis and Osteoblast Precursors
Christa Maes, Sonia Bartunkova, Katharina Haigh, Sophie Torrekens, Riet Van Looveren, Anna Chan, Andras Nagy, **Jody Haigh**, Geert Carmeliet
Bone 46, S53, 2010

8. VEGF is a novel guidance cue for the initiation of granule cell radial migration
C Ruiz De Almodovar, C Meissirel, P Salin, N Chounlamountri, M Mutin, Erik Storkebaum, U Eriksson, **Jody Haigh**, MF Belin, Lieve Moons, Peter Carmeliet, N Thomasset
Journal of Neurochemistry 102, 253-253, 2007

7. Vegf is a guidance signal for granular cell during cerebellar development.
C Meissirel, PA Salin, N Chounlamountri, M Mutin, **J Haigh**, MF Belin, L Moons, P Carmeliet, N Thomasset.
Differentiation 74 (8), 462-463, 2007

6. The effect of different VEGF isoforms on mesoderm in the early mouse embryo
S van George, A Chan, **J Haigh**, A Nagy
Vascular Pharmacology 45 (3), e39-e40, 2006

5. Basic Science Articles-Pathophysiology of Renal Disease and Progression-Vascular Endothelial Growth Factor A Signaling in the Podocyte-Endothelial Compartment Is Required for Mesangial Cell
Vera Eremina, Shiying Cui, Hanspeter Gerber, Napoleone Ferrara, **Jody Haigh**, Andras Nagy, Masatsugu Ema, Janet Rossant, Serge Jothy, Jeffrey H Miner, Susan E Quaggin
Journal of the American Society of Nephrology 17 (3), 724-735, 2006

4. Aberrant bone formation in mice over-expressing specific VEGF isoforms in cartilage.
C Maes, **J Haigh**, A Chan, K Haigh, R Bouillon, G Carmeliet, A Nagy
Annual Meeting of the American Society for Bone and Mineral Research
Journal of Bone and Mineral Research 20 (9), 39, 2005

3. HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY-Activated Fps/Fes partially rescues the in vivo developmental potential of Flk1-deficient vascular progenitor cells
JJ Haigh, M Ema, K Haigh, M Gertsenstein, P Greer, J Rossant, A Nagy, EF Wagner
Blood 103 (3), 912-920, 2004

2. VEGF-A signaling in the glomerulus.
V Eremina, **J Haigh**, A Nagy, SE Quaggin
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14, 25A-25A, 2003

1. Lack of vascular endothelial cell growth factor (VEGF) in murine epidermal keratinocytes results in retardation of angiogenesis-dependent processes in the skin
H Rossiter, C Barresi, J Ban, C Mayer, **J Haigh**, E Wagner, E Tschachler
JOURNAL OF INVESTIGATIVE DERMATOLOGY 117 (2), 391-391, 2001

Summary of Conference Invitations and Presentations

2023

- Conference on Signalling in Normal and Cancer Cells, April 23-27 2023, Banff, Alberta, Canada
  Attendee

- 5th International Conference on Cytokines in Cancer Meeting. May 13-18 2023, Kos, Greece
  Speaker

2021

National

- Canadian Society of Pharmacology and Therpeutics Annual Meeting. June 10-12 *Targeting novel (epi)genetic factors to improve therapeutic outcomes in blood cancers.* Virtual
  Invited Speaker

2020

National

- Canadian Society of Pharmacology and Therpeutics Annual Meeting. Ottawa, Canada, June 10-12 *Targeting novel (epi)genetic factors to improve therapeutic outcomes in blood cancers.* Cancelled
  Invited Speaker

2019

National

- Till & McCullough Stem Cell meeting, Montreal, Canada November 4-6. *The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.*
  poster presenter and poster judge

International

- Hallmarks of Cancer Symposium-Cell Press, Seattle, Washington, USA November 17-19. *The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.*
  poster presenter

2018

National

- Till & McCullough Stem Cell meeting, Montreal, Canada November 4-6. **attendee and poster judge**

- ISSCR Meeting, Melbourne Australia
  June 20-23, **attendee**

2017

National

- New Directions in Leukaemia Research (NDLR) bi-annual meeting**.** Brisbane, Australia, March 25-28.

  - The EMT transcription factor Zeb1 is essential for murine myeloid differentiation: a potential therapeutic target in acute myeloid leukaemia?

  poster presenter
  - *The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.*
  poster presenter

2016

International:

- The First Harbin International Symposium on Leukaemia and Other Malignancies: Pathogenesis and Therapeutics, **Invited Keynote Speaker**, Harbin, China (declined)

- International Society for Stem Cell Research (ISSCR) Annual Meeting, San Francisco, USA June 22-25. *The novel T-ALL driver Zeb2 associates with NURD/LSD1 protein complexes and is correlated with increased LSD1 inhibitor sensitivity.*
  poster presenter

National:

- Australasian Society for Stem Cell Research (ASSCR) annual meeting, **Ph.D. Poster and Oral Presentation Judge**, Perth, Australia

- New Directions in Leukaemia Research (NDLR) bi-annual meeting-**Invited oral presentation** (given by my former postdoc Dr. Steven Goossens), Noosa, Australia

- Monash University Heart Research Symposium, Melbourne Australia, November 3. *Harnessing cellular plasticity, memory and directed differentiation in cardiac repair.*
  Invited Speaker

2015

International:

- International Society for Experimental Haematology (ISEH) Annual Meeting, Kyoto, Japan. September 17-19. *The novel T-ALL driver Zeb2 associates with NURD/LSD1 protein complexes and is correlated with increased LSD1 inhibitor sensitivity.*
  poster presentation

National:

- International EMT Bi-annual Conference (TEMTIA), Melbourne, Australia. October 11-14. *The EMT modulator Zeb2 is a novel driver of aggressive forms of T-cell leukemia.*
  Invited Speaker

- Lorne Cancer Conference, Lorne, Australia, February 12-14. *The EMT modulator Zeb2 is a novel driver of aggressive forms of T-cell leukemia.*
  poster presentation

- Australasian Society for Stem Cell Research (ASSCR) annual meeting, Hunter Valley, Sydney Australia. November 8-10.
  Young investigator event panel member

2014

International:

- International Society for Stem Cell Research (ISSCR) Annual Meeting, Vancouver, Canada. June 18-21. *Zeb2 drives T-cell lymphoblastic leukemia development via altered IL-7 receptor signaling and enhanced tumour-initiating potential.*
  Invited Speaker

National:

- 2nd Cell Reprogramming Australia's The Making of Reprogramming Conference, Melbourne, Australia. May5-6. *Novel Models to study cellular reprogramming, memory, and transformation.*
  Invited Speaker

- 7th International Garvan Signalling Symposium, Sydney, Australia. October 13-14. Novel roles for the Zeb2 transcription factor in hematopoiesis and leukemia
  Invited Speaker

- New Directions in Leukemia Research (NDLR), Noosa, Australia. March 30-April 2. *Zeb2 drives T-cell lymphoblastic leukemia development via enhanced IL-7R signaling and enhanced tumour initiation potential.*
  Plenary Speaker

- Australian Vascular and Cardiac Biologist Meeting, **attendee**, Melbourne, Australia

2013

International

- International Society for Stem Cell Research (ISSCR) Annual Meeting, Boston, USA. June 12-15. *Zeb2 drives T-cell lymphoblastic leukemia development via altered IL-7 receptor signaling and enhanced tumour-initiating potential.*
  Invited Sessional Speaker

- 6th meeting for "Le Club des Belles Souris"-The nice mouse club-mouse genetics meetings, Montpellier, France. April 2013. *Novel conditional and inducible models to study cellular (de)differentiation.*
  Invited Speaker

2012

International

- 1st International Aegean conference on Stem Cell Biology, **Invited Speaker,** Crete, Greece

National

- Cell Symposia on Angiogenesis, Metabolic Regulation, and Cancer Biology, poster presentation Leuven, Belgium, 2012.

2011

International

- Sixth International Workshop on Innovative Mouse Models, **Plenary Speaker**, Lieden, The Netherlands
- International Society for Stem Cell Research (ISSCR) Annual Meeting, **poster presentation**, Toronto, Canada

2010

International

- North American Vascular Biology Organisation (NAVBO) Developmental Vascular Biology Workshop IV, **poster presentation**, Pacific Grove California

National

- 8th International Conference on BMPs, **Session Chair**, Leuven, Belgium

2009

International

- 14th International European Hematology Association (EHA) Conference, **Plenary Speaker** Berlin, Germany

2008

International

- North American Vascular Biology Organisation (NAVBO) Developmental Vascular Biology Workshop III, **poster presentation**, Pacific Grove California
- Second International Conference on Osteoimmunology-Interactions of the immune and skeletal systems, **Plenary Speaker**, Rhodes, Greece

2007

International

- 4th International Workshop on Innovative Mouse Models, **Plenary Speaker**, Lieden, The Netherlands
- 7th ESH Euroconference on Angiogenesis, **poster presentation**, Albufeira, Portugal

2006

International

- 1st International Conference on Osteoimmunology-Interactions of the immune and skeletal systems. **poster presenter** Knossos, Crete
- Cell Signaling World-Signal transduction pathways as therapeutic targets, **participant**, Kirchberg, Luxembourg.
- North American Vascular Biology Organization-Developmental Vascular Biology Workshop II, **poster presenter**, Pacific Grove, USA.

2005

International

- 13th International IMP Spring Conference (1st IMBA inarguable conference), **Plenary Speaker**, Vienna, Austria
- 3rd International Workshop on Innovative Mouse Models, **Plenary Speaker**, Leiden, Netherlands.
- Gordon Research Conference-'Angiogenesis and Microcirculation'. **poster presenter**, Newport, Rhode Island, USA. August 14th-19th, 2005.

2004

International

- European Molecular Biology Laboratory (EMBL) 'Oncogenes and Growth Control' meeting, **Plenary Speaker**, Heidelberg, Germany

Summary of Institutional Seminar Invitations

- Dr. Christopher Maxwell, BC Children's Hospital Research Institute, UBC 2022 (Virtual)
- Dr. Ed Conway, Director of Blood Research Center, UBC 2019
- Dr. Paul Fernyhough, Department of Pharmacology & Therapeutic, University of Manitoba 2017
- Dr. Maxime Bouchard, Goodman Cancer Centre, McGill University 2017
- Dr. Timothy Newsome, University of Sydney, Sydney, Australia 2014
- Dr. Quentin Schwarz, University of Adelaide, Adelaide, Australia 2014
- Dr. Paul Timpson, Garvan Research Institute, Sydney, Australia 2014
- Dr. Frank Gannon-Queensland Institute for Medical Research, Brisbane, Australia 2012
- Dr. David Curtis-Australian Center for Blood Diseases, Alfred Hospital, Monash University, Melbourne, Australia 2012
- Dr. Bob Graham-Victor Chang Cardiac Research Center, Sydney, Australia-2011
- Dr. Walter Thomas-School of Biomedical Sciences, University of Queensland, Brisbane, Australia 2011
- Dr. Peter Greer, Queen's University, Kingson, Canada 2010
- Dr. Axel Behrens-Cancer Research UK, London, UK 2009
- Dr. Kurt Balmer-Hofer, Paul Sherrer Institute, Villigen, Switzerland 2008
- Dr. Yotis Senis, Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, UK 2008
- Dr. Karen Vousden, Beatson Institute for Cancer Research, Glasgow, Scotland 2008
- Dr. Dagmar Wirth, Helmholtz Zentrum für Infektionsforschung, Braunshweig, Germany 2007
- Dr. Jean-Pierre David, DRFZ, Berlin, Germany 2006
- Dr. Josef Penninger, IMBA,Vienna, Austria 2006
- Dr. Pantelis Georgiades, Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus 2006
- Dr. Christiana Ruhrberg, University College London, Dept. for Ophthalmology, London, United Kingdom 2005
- Dr. Jan Tuckermann, Institute of Molecular Biotechnology, Jena, Germany, 2005
- Dr. Jean-Paul Hermann, CNRS-Univ. de l'Mediterrannée, Marseille, France 2005
- Dr. Harry Heimberg, Vrije Universiteit Brussels, Diabetes Research Center 2005

- Dr. Pierre Vanderhaeghen, IRIBHM, ULB Campus Ersame, Brussels 2005
- Dr. Danny Huylebroeck, Department of Molecular and Developmental Genetics- Leuven 2004
- Dr. Frans Van Roy, Department for Molecular Biomedical Research, Ghent, Belgium 2004
- Dr. Austin Smith, University of Edinburgh, Scotland 2004
- Dr. Tony Green, Addenbrooke's Hospital, University of Cambridge, UK 2004
- Dr. Janet Rossant, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 2000
- Dr. Napoleone Ferrara, Genentech, San Francisco, USA 2000

Industrial Income and Intellectual Property

Industrial Income

- Year: 2007
  Short Name: Generation of mouse models of metabolic disease
  Type: Joint venture with commercial interests (DevGen)
  Your Role: Principal Investigator
  Brief Description: Provided industrial income of $386K for lab. Industrial research grant with DevGen(SME). Recent Nature Immunology paper was published (Hammad et al. Nature Immunlogy, 2017) using mice generated by my lab during this project.
  Funding Source: Flemish Industrial Research Fund (IWT)

Intellectual Property

- More than **100 Material Transfer Agreements (MTAs)** have been issued by my former Institute, the VIB/Ghent University concerning the distribution and use of the DNA plasmids and mouse models that my lab has generated that are outlined below:

Research Tools

- Year: **2013**
  Short Name: **Efficient generation of COIN Alleles in mouse**
  Type: Animal Model
  Your Role: Principal Investigator
  Brief Description: Haenebalcke et al., *Stem Cell Reviews and Reports*. The conditional Cre/loxP system and/or the doxycycline (Dox) inducible Tet-on/off system are widely used in mouse transgenesis but often require time consuming, inefficient cloning/screening steps and extensive mouse breeding strategies. We have therefore developed a highly efficient Gateway-and recombinase-mediated cassette exchange (RMCE)-compatible system to target conditional and/or inducible constructs to the ROSA26 locus of F1 hybrid Bl6/129ESCs, called G4 ROSA-LUC-ESCs. By combining the Cre/loxP system with or without the inducible Tet-on system using Gateway cloning, we can rapidly generate spatial and/or temporal controllable gain-of-function constructs that can be targeted to the RMCE-

compatible ROSA26 locus of the G4 ROSA-LUC-ESCs with efficiencies close to 100%. These novel ESC-based technologies allow for the creation of multiple gain-of-function conditional and/or inducible transgenic ESC clones and mouse lines in a highly efficient and locus specific manner. Importantly, incorporating insulator sequences into the Dox-inducible vector system resulted in robust, stable transgene expression in undifferentiated ESCs but could not fully overcome transgene mosaicism in the differentiated state. Funding Source: FWO

- Year: **2013**
  Short Name: **Generation of novel reprogramming mouse model**
  Type: Animal Model
  Your Role: Principal Investigator
  Brief Description: Haenebalcke et al., *Cell Reports*. Control of cellular (de)differentiation in a temporal, cell-specific,and exchangeable manner is of paramount importance in the field of reprogramming. Here, we have generated and characterized a mouse strain that allows iPSC generation through the Cre/loxP conditional and doxycycline/rtTA-controlled inducible expression of the OSKM reprogramming factors entirely from with in the ROSA26 locus . After reprogramming, these factors can be replaced by genes of interest—for example, to enhance lineage-directed differentiation—with the use of a trap- coupled RMCE reaction. We show that, similar to ESCs,Dox-controlled expression of the cardiac transcriptional regulator Mesp1 together with Wnt inhibition enhances the generation of functional cardiomyocytes upon in vitro differentiation of such RMCE-retargeted iPSCs. This ROSA26-iPSC mouse model is therefore an excellent tool for studying both cellular reprogramming and lineage-directed differentiation factors from the same locus and will greatly facilitate the identification and ease of functional characterization of the genetic/epigenetic determinants involved in these complex processes.
  Funding Source: FWO, BFAC

- Year: **2010**
  Short Name: **Generation of conditional R26-VEGF164 transgenic mouse**
  Type: Animal Model
  Your Role: Principal Investigator
  Brief Description: Maes et al., *EMBO Journal*, 2010 (>90 citations). In this paper we developed a mouse model that allows the conditional, cell specific expression of the VEGF164 allele to study the role of enhanced vasculature on organ development and disease processes. In this publication we showed how increased VEGF164 expression is coupled to increased bone formation through activation of beta-catenin. We have also used this mouse model to investigate the role of VEGF164 in skin cancer stem cells. This hallmark finding was published in Nature (Beck et al., 2011) and has been cited >200 times.

- Year: **2009**
  Short Name: **Generation of conditional Snai1 and Zeb2 transgenic mice**
  Type: Animal Model
  Your Role: Principal Investigator
  Brief Description: We have used our R26 conditional transgenic approaches to create conditional Snai1 and Zeb2 expressing mice to study the role of these important

transcription factors in many developmental and cancer related processes. Publications include Horvath et al (EMBO J, 2015) concerning the role of Snai1 in intestinal stem cell maintenance, as well as the role of Zeb2 in skin barrier function (Tatari et al., 2014) as well as melanocyte differentiation and melanoma progression (Denecker et al., 2014) as well as our recent Nature Communications papers concerning the role of Zeb2 in T-ALL (Goossens et al., 2015) and the roles of Zeb2 in T and NK development and function (Omilusik et al., 2015 JEM, Van Helden et al., JEM 2015).
Funding Source: FWO

- Year: **2009**
  Short Name: **Efficient Generation of Rosa26 transgenics**
  Type: Animal Model
  Your Role: Principal Investigator
  Brief Description: Nyabi, O., et al., *Nucleic Acids Res.*, 2009 (>50 citations). In this publication my lab generated novel technologies for efficiently generating Cre/loxP conditional ROSA26 locus based transgenic mice. These technologies form the basis of numerous international and industrial collaborations where we have generated novel and relevant mouse models for studying aspects of human disease. The reagents in this paper have been widely distributed throughout the world.

Collaborations

Past collaborations:

Since starting my own research lab at the VIB, Belgium in 2004 I have had numerous national/international collaborations with excellent outcomes. These collaborations were mainly based upon my expertise in mouse transgenic technologies, VEGF and EMT transcription factor biology. These include:

- Geert Berx (DMBR-VIB/UGent, Belgium): My lab initiated and generated transgenic mice to study EMT modulators of Snai and Zeb family in cardiovascular biology and cancer progression that resulted in 18 publications, 1 shared international grant to AICR (Worldwide Cancer Research).

- Chris Marine (VIB-Leuven, Belgium): My lab was sought out to create important mouse models to study p53 modulators mdm2/4 in cancer progression that resulted in 6 publications, including one in ***Nature Medicine*** and involved co-supervision of 2 PhD students.

- DeVgen (SME, Ghent, Belgium) Industrial project grant (IWT, 2006-2009). Here my lab was sought out by DeVgen to create mouse models to study metabolic diseases and provided industrial lab income ($386K). Taok3 null mice generated by my lab during this work was recently published (Hammad et al., ***Nature Immunology***, 2017) concerning marginal zone B-cell development.

- Peter Carmeliet (VIB-Leuven, Belgium): I initiated collaborations with this group and provided expertise and key mouse reagents for studying the role of VEGF in various organogenesis and disease related studies that resulted in 6 publications and 1 book review chapter, co-participation in 1 Belgium-wide IUAP grant network.

- Throughout my career I have either actively sought out or have been sought out for my expertise and established a truly excellent international collaborative network with leaders in their fields. Some examples include Pieter Van Vlierberghe-Ghent, Belgium (2 research articles, 1 review, Worldwide Cancer Research Grant), Cedric Blanpain-Brussels, Belgium (***Nature*** paper), Axel Behrens-London, UK (***NCB*** paper), Fanny Mann- Paris, France (***Neuron*** paper).

More recent collaborations:

- Australia local (ACBD)- A/Prof. David Curtis: Based upon my expertise in mouse transgenesis I generated novel PRMT5 mouse resources for studying its role in cancer stem cell biology (co-investigator on NHMRC project). I previously established a research consortium between researchers at the ACBD (Andrew Wei, David Curtis) and A/Prof. Jose Polo (Australian Regenerative Medicine Institute-ARMI) concerning the characterization and use of AML-iPS cells to study AML. My expertise has been sought out by Prof. Steven Jane (head of Central Clinical School, Monash) and have generated conditional R26-Grhl3 transgenic mice to examine the role of Grainyhead-like 3 protein in development and cancer.

- Australia National: From talks given at national cancer research meetings I have established national collaborations and include those with the group of A/Prof. Paul Timpson (Garvan Research Institute, Sydney) based upon our expertise in mouse transgenic technologies where we have created conditional R26 Akt and Src biosensor mice for the real time monitoring of kinase activity in vivo during cancer progression. As well, I have actively established collaborations with the group of Prof. Richard Lock (Children's Cancer Institute, Sydney) concerning the use of human ETP-ALL and AML primographs with KDM1A inhibitors. As well, I have established collaborations with Prof. John Pimanda (UNSW, Sydney) concerning RNA and ChIPseq experiments outlines in this proposal.

- International: I have actively sought out and established research collaborations with expert international groups including Prof. Cristina Mecucci (University of Perugia, Italy-co-invetigator for NHMRC grant -1 co-author Blood publication), A/Prof. Pieter Van Vlierberghe (Ghent University, Belgium-see papers above) and Prof. Geert Berx (VIB, Belgium-see papers above) and recently established collaborations with Prof. David Pellman (Harvard University, USA) for studies on the role of ZEB2 and SNAI1 in AML. Recently have been entending previous collaborations with the group of Prof. Josef Penninger where out lab has generated R26 locus based condtional humanized hACE2 mouse models for studying SARS-CoV-2 induced pathologies in COVID-19 patients.

Teaching and Supervisory Accomplishments

(August 2018-present) Started out **75% Research, 25% Teaching and Service** and this has changed to **60% Research**, **40% Teaching and Service Position**

Teaching

This is first tenure-track position that I have been in as previously I was in 100% Research Only positions in Australia (Associate Professor) and Belgium (Assistant Professor and Group Leader).

- **PHAC2100** 4hrs (February 2019-onwards)
  - Teaching in the area of Cancer Pharmacology, Thyroid Pharmacology
- **PHAC3000** 4hrs (2021-onwards)
  - Teaching in the area of Nuclear Receptors and Pharmacology
- **PHAC7240**- 2hrs (February 2020-onwards)
  - Teaching in the area of Cancer Pharmacology
- P**HAC7136**-4hrs (September 2019-onwards)
  - Teaching in Area of Blood Cancer Pharmacology
- **IMED 7200**-2 hrs (March 2020-onwards), Cancer Biology, Department of Internal Medicine
- **PHAC4040** Winter 2021-onwards, 2 hrs thyroid and pregnancy
- **RESP1440** Winter 2021-onwards, 1 hr on anti-coagulants/thrombotics
- **MDFY2030** Winter 2022-onwards, 1 hr on vaccines and immunoglobulins

Total teaching: 20 student teaching contact hrs

Supervision

Present Members:

- 1 Research Technician
  - Katharina Haigh

- 1 Research Associates
  - Dr. Andrew Cuddihy

- 1 M.Sc. Student
  - Tyler Anderson (September 2021-present)

Previous members:

- 1 Research Associate
  - Dr. Aissa Benyoucef (March 2020-May 2022)

- 1 Postdoctoral Fellow

- Dr. Carlos Farkas (March 2020-July 2021), Group leader in Chilé

- 1 M.Sc. student
  - Mr. Vignesh Krishnamoorthy, (Indian Foreign Student) started September 2019-Defended April 2022
    - Recipient of Dr. Mark Nickerson Graduate Entrance Scholarship in Pharmacology and Therapeutics for highest entering GPA

- Summer 2019 supervised Mr. Jacky Wang and Mr. Tommy Guo as undergraduate summer students

- Summer 2021 supervised summer student Cassandra Schroeder

Monash University (August 2013-July-2018) **100% Research Position**

Teaching

At Monash University I taught a small number of courses in Human Pathology and Immunology

- **HUP3022** 1hr guest lecture in 2016 and 2017
  - Lecture on "Gene Modification Approaches"
  - Lecture on "Harnessing stem cell technologies in hematological disease."

Supervision

Summary Table of Supervision

Name	Year	My Role	Level	Their Current Role	Comments
Dr. Catherine Carmichael	2013-2018	Supervisor	PDF	**Group Leader,** ACBD Monash University	-Blood manuscript in revision, 3 co-authorship pubs
Dr. Maggie Costa	2013-2018	Supervisor	PDF	ACBD FACS Facility Monash University	2 co-authorship pubs
Dr. Jacky Wang	2016-2019	Supervisor	PDF	Job in **Pharma,** Australia	2 co-authorship pubs
Dr. Steven Goossens	2014-2015	Supervisor	Visiting PDF	**Professor,** Ghent University, Belgium	31 co-authorship pubs -FWO funded PDF -EHA PDF award
Dr. Thao Nguyen	2013-2018	Supervisor	Technician	Technician, Monash University, Australia	3 co-author pubs
Katharina Haigh	2013-2018	Supervisor	Technician	Lab Manager, Haigh Lab University of Manitoba	24 co-authorship pubs
Mina Takawy	2015-2020	Co-supervisor	PhD	Writing up PhD Monash University	1 co-author Blood pub
Charlotte De Mazière	2016-2017	Co-supervisor	Visiting M.Sc.	PhD in Belgium	Blood co-author publication
Anna Milne	2017-2018	Supervisor	B.Sc.H. HUP3990 Summer Student	Medical School	Blood co-author publication
Max Garwood	2017-2018	Supervisor	B.Sc.H.	Research Assistant ACBD, Monash	-
William McInnes	2016-2017	Supervisor	B.Sc.H.	Works in Biotech Sector	Blood co-author publication
Adam Rickard	2015-2016	Supervisor	B.Sc.H.	Unknown	1 Nature Comm co-author pub
Natasha Mezhov	2015-2016	Supervisor	HUP3990 Summer	Registered Nurse	-

VIB/Ghent University (August 1, 2004-July 1, 2013)

90% Research Position, 10% Supervision and Service

- From 2004-2009 I was a group leader within the Department for Molecular Biomedical Research (DMBR) at the Flanders Institute of Biotechnology (VIB), an independent institute with an affiliation with the University of Ghent. Although this role afforded several advantages, the Institutes' affiliation was insufficient for me to apply independently for local funding or act independently to promote my students and fellows. (In Flanders, one has to have personal university affiliation to apply independently for funding at the FWO (CIHR equivalent) or to act as a supervisor of Ph.D. students). This severely limited the growth potential of my lab. In particular this had an effect on the number of PhD students I was able to mentor and supervise. I was granted university title of assistant professor in November 2009.

- This situation had the beneficial effect that it encouraged me to collaborate much more effectively with people in order to apply for FWO funding in Belgium (2004-2009). Once granted a university appointment (10%) I successfully obtained my own independent FWO funding and acted as PhD supervisor for 2 students who successfully completed their PhD degrees (2012).

Teaching

Guest lecturer in Graduate Cancer Biology Course (Course Coordinator Dr. Geert Berx)

- 2 hrs lecture on Mouse Models of Cancer in 2010 and 2011

- 2hrs lecture on Antiangiogenetic Therapies in Cancer in 2011

Supervision

Summary Table of Supervision

Name	Year	My Role	Level	Their Current Role	Comments
Dr. Tim Pieters	2011-2013	Supervisor	PDF	Postdoc in Ghent Belgium	-10 co-authorship pubs
Dr. Steven Goossens	2007-2013	Supervisor	PDF	**Professor,** Ghent University, Belgium	31 co-authorship pubs -FWO funded PDF -EHA PDF award
Dr. Benjamin Drogat	2006-2010	Supervisor	PDF	Research Associate in Belgium	8 co-authorship pubs
Dr. Omar Nyabi	2005-2009	Supervisor	PDF	Research Associate in Belgium	5 co-authorship pubs
Dr. Sonia Bartunkova	2013-2018	Supervisor	Technician	retired	10 co-authorships
Michael Naessens	2006-2008	Supervisor	Technician	unknown	5 co-authorship pubs
Katharina Haigh	2004-2013	Supervisor	Technician	Lab Manager, Haigh Lab University of Manitoba	24 co-authorship pubs
Lieven Haenebalccke	2007-2012	Supervisor	Ph.D. M.Sc.	**Sr. Manager** Bioanalytical labs, **Pfizer**, Belgium	13 co-authorship pubs, IWT studentship recipient
Morvarid Farhang Ghahremani	2007-2012	Co-supervisor	Ph.D.	Works in Biotech sector	5 co-author pubs, Intl PhD student
Pieterjan Dierickx	2011-2012	Supervisor	M.Sc.	**Group Leader in Germany**	2 co-author pubs
Karolina Slowicka	2012-2013	Supervisor	M.Sc.	PDF in Belgium	2 co-author pubs
Bouchra Nouman	2006-2007	supervisor	M.Sc.	Unknown	-

Katrien Verwaest	2008-2009	Supervisor	M.Sc.	PDF in Belgium	-
Steven Cool	2008-2009	Supervisor	M.Sc.	PDF in Belgium	-
Sara Corradi	2009-2010	Supervisor	M.Sc.	PDF in Belgium	-
Johanna Kalucka	2008-2009	Supervisor	M.Sc.	**Assistant Professor** in Denmark	Co-author Blood publication
Joseph Reagan	2004-2005	Supervisor	M.Sc.	Research Scientist at Innovative Medicines Initiative	-
Mark Rogers	2004-2005	Supervisor	M.Sc.	**CEO** of BioXplor Biotech firm	On their advisory board

In total have supervised/mentored **38 people** in my career including 4 technicians, 4 summer, 4 B.Sc.H., 13 M.Sc., 3 Ph.D. students and 8 postdoctoral fellows (PDFs) and 2 research associates. **Five** of these researchers have gone on to become independent group leaders in academia or have pursued careers in biotechnology/phamaceutical industry (**6**) or as PDF/research associates in science (**7**).

Academic Service Accomplishments

(August 2018-present) Started out **75% Research, 25% Teaching and Service** and this has changed to **60% Research**, **40% Teaching and Service Position**

Local

➔ December 2021-March 31, 2023 was acting co-Director and member of interim leadership team.

- Lead in new faculty recruitment, institutional renovation planning
- Assist in acquisition and implementation of new technology platforms
- Participate in daily running of CCMR

➔In mid-2020 became Head of CCMR Cancer Modelling and Imaging Core Facility

- Generation and maintenance of facility that will provide researchers with affordable immunocompromised NSG mice for performing cancer patient primary tumour cell xenotransplant translational models
- This platform has expanded and is now known **as Cancer Modelling and Imaging Centre (CMIC)**. Centre provides R26 locus based GEMM models (using my lab's technologies) and capacity to perform in vivo tumour imaging with AMI in vivo bioluminescence imager (purchased with my CFI/JELF).

- Course Co-coordinator **PHAC2100** (with Dr. Jill Stobart)
  - Coordinating scheduling, exam preparation and invigilator

- M.Sc. external thesis committee member
  - Odile Huynh (lab of Dr. Sachin Katyal, Pharmacology and Therapeutics)
  - Kailee Rutherford (lab of Dr. Kirk McManus, Biochemistry and Human Genetics)

- External Ph.D. Evaluation committee for Patrick Coulombe in the lab of Prof. Aly Karsan

- Selection committee member for Sara Israel's annual best graduate thesis award winner (2020)

- Department of Pharmacology and Therapeutics Graduate Student Committee member

- Member of Bannatyne Campus Local Animal Users Committee (2020)

National

- Grant Panel Review Member for Cancer Research Society (CRS), Canada (since 2023)

- Member of Research Manitoba New Investigator Award selection committee (since 2020)

- Member of Michael Smith Foundation postdoctoral fellow selection committee (since 2019) **Chair** 2022-2023

- CIHR College of Reviewers (since 2019), CPT (2) panel member (Since 2021)

- NSERC Grant external reviewer (since 2019)

International

- Advisory Board Member-BioXplor Inc.
  - CEO Mark Rogers (former M.Sc. student Haigh lab-deceased)

- External Grant Reviewer for F.R.S./F.N.R.S. Belgium

- Guest Editor for Biomolecules Journal
  - Topic "Role of EMT Transcription Factors in Hematopoietic Development, Immune Cell Function and Leukemic Transformation

- Guest Editor for Biomolecules Journal
  - Topic *"VEGF biology and therapeutic applications"*

- Guest Editor for AIMS Cell and Tissue Engineering Journal
  - Topic "iPS Cell Technologies in Human Diseases (2018)

- Ad hoc reviewer for following journals:
  - *Molecular Psychiatry (2019)*
  - *Frontiers Cell and Developmental Biology (2019)*
  - *Nature Communications (2018)*
  - *Frontiers in Genetics (2018)*
  - *Stem Cells and Development (2018)*

Monash University (August 2013-July-2018) **100% Research Position**

Local

- Monash University Ph.D. external committee member
  - Shauna French (Lab of Ass. Prof. Justin Hamilton)
  - Ashley Conway (Lab of Prof. David Curtis)
  - Reyhan Akhtar (Lab of Ass. Prof Helen Abud)

- Chair of ACBD senior group leader management committee (2014-2015)
  - responsible for chairing monthly meetings concerning recruitment strategy and departmental operational matters

National

- NHMRC Project Grant Review Panel Member (2017-2019)

- Australian Academy of Sciences-Rapporteur for Theo Murphy Think Tank on Regenerative Medicine (2015)
  - Responsible for co-writing policy document concerning the future needs of regenerative medicine research in Australia to be read by public, media and government policy makers

International

- External Grant Reviewer for F.R.S./F.N.R.S. Belgium

- Ad hoc reviewer for the following journals:
  - Aims Cell and Tissue Engineering (6X) (2016-2018)
  - Stem Cells and Development (2015)
  - Frontiers in Genetics (2015)
  - Stem Cell Reports (2015)
  - Critical Reviewers in Immunology (2015)
  - Jove (2014)
  - Journal of Molecular Biology (2014)
  - FASEB Journal (2014)
  - Cell and Tissue Research (2014)

VIB/Ghent University (August 1, 2004-July 1, 2013) **90% Research Position**

Local

- Ghent University Ph.D. completion committee membership
  - Mathias Fransen (Lab of Dr. Kris Vleminkx, 2012)
  - David Nittner (Lab of Dr. Chris Marine, 2012)
  - Ivan Moya (Lab of Dr. An Zwijsen, 2012)
  - Davina Tondeleir (Lab of Dr. Christophe Ampe)
  - Michael Devos (Lab of Dr. Wim Declerc, 2013)
  - Marianthi Tatari (Lab of Dr. Geert Berx, 2011)
  - Tim Pieters (Lab of Dr. Frans Van Roy, 2011)
  - Xiangwei Xiao (Lab of Dr. Harry Heiman, 2011)
  - Kristof Kersse (Lab of Dr. Frans Van Roy, 2011)
  - Margarita Maia (Lab of Dr. Ed Conway, 2010)
  - Eline Dejonckheere (Lab of Dr. Clause Libert, 2010)
  - Robrecht Thoonen (Lab of Dr. Peter Brouckaert, 2010)
  - Hong Thi Tran (Lab of Dr. Kris Vleminkx, 2010)
  - Chantal Beekman (Lab of Dr. Chris Marine, 2009)
  - Liesbeth Vermieire (Lab of Danny Huylebroecke, 2009)
  - Marion Maetens (Lab of Dr. Chris Marine, 2008)
  - Femke Zwerts (Lab of Dr. Ed Conway, 2007)
  - Karl Vandepoele (Lab of Dr. Frans Van Roy, 2006)
  - Tina Mahieu (Lab of Dr. Claude Libert, 2006)

- Co-Chair of Tissue Morphogenesis and Disease Program IRC/VIB (2011-2013)

- VIB co-chair for Group Leader Committee (2012-2013)
  - Responsible for helping in the selection of international PhD students for VIB international PhD program and in representing over 70 group leaders concerning operational matters.

National

- FWO, Belgium External Reviewer (2012-2013)

- FNRS-Walonia Belgium-Fellowship and Grant Panel Review Member (2012-2013)

International

- Expert international panel member Cancer Research UK (2013)
  - Involved in writing a review of Cancer Resarch UK's mouse transgenesis facility and in giving advice on mouse transgenesis technologies